Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

16
results for

"Radiotherapy"

Article category

Keywords

Publication year

"Radiotherapy"

Editorial

Hepatic neoplasm

Citations

Citations to this article as recorded by  Crossref logo
  • Triterpenes from Ganoderma lucidum inhibit hepatocellular carcinoma by regulating enhancer-associated lncRNA in vivo
    Ruolin Zhao, Caiyun Zhang, Chenchen Tang, Xinxin Wu, Sheng Hu, Qingqiong Luo, Ning Jia, Lingzhi Fan, Yixing Wang, Wencheng Jiang, Qilong Chen
    Journal of Ethnopharmacology.2025; 336: 118706.     CrossRef
  • Intelligent Hydrogel-Assisted Hepatocellular Carcinoma Therapy
    Zixiang Tang, Lin Deng, Jing Zhang, Tao Jiang, Honglin Xiang, Yanyang Chen, Huzhe Liu, Zhengwei Cai, Wenguo Cui, Yongfu Xiong
    Research.2024;[Epub]     CrossRef
  • 6,194 View
  • 52 Download
  • 2 Web of Science
  • Crossref

Reviews

Hepatic neoplasm

Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma
Sung Uk Lee, Tae Hyun Kim
Clin Mol Hepatol 2023;29(4):958-968.
Published online August 29, 2023
DOI: https://doi.org/10.3350/cmh.2023.0274
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, and external beam radiation therapy has emerged as a promising approach for managing HCC. Proton beam therapy (PBT) offers dosimetric advantages over X-ray therapy, with superior physical properties known as the Bragg peak. PBT holds promise for reducing hepatotoxicity and allowing safe dose-escalation to the tumor. It has been tried in various clinical conditions and has shown promising local tumor control and survival outcomes. A recent phase III trial demonstrated the non-inferiority of PBT in local tumor control compared to current standard radiofrequency ablation in early-stage HCC. PBT also tended to show more favorable outcomes compared to transarterial chemoembolization in the intermediate stage, and has proven effective in-field disease control and safe toxicity profiles in advanced HCC. In this review, we discuss the rationale, clinical studies, optimal indication, and future directions of PBT in HCC treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • Mitochondria-Targeted Icaritin Nanoparticles Induce Immunogenic Cell Death in Hepatocellular Carcinoma
    Siyu Chen, Yiyang Sun, Yangla Xie, Yanpeng Liu, Haitao Hu, Chang Xie, Shengjun Xu, Zhouxing Zhang, Jing Zhang, Youqing Shen, Xiao Xu, Nasha Qiu
    ACS Applied Materials & Interfaces.2025; 17(2): 2899.     CrossRef
  • Comparison of Prognostic Outcomes Between Repeat Liver Resection and Particle Therapy for Patients with Recurrent Hepatocellular Carcinoma
    Tatsuki Kusuhara, Hidetoshi Gon, Kazuki Terashima, Shohei Komatsu, Yoshiro Matsuo, Sunao Tokumaru, Hirochika Toyama, Masahiro Kido, Tomoaki Okimoto, Takumi Fukumoto
    Annals of Surgical Oncology.2025; 32(2): 1073.     CrossRef
  • Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
    Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S228.     CrossRef
  • Efficacy and safety of radiotherapy combined with immune checkpoint inhibitors for advanced or unresectable hepatocellular carcinoma: A systematic review and meta-analysis
    Qibin Wu, Xia Zhao, Chong Yang, Yinglin Yuan, Hongji Yang, Qiang Fu
    Critical Reviews in Oncology/Hematology.2025; 211: 104730.     CrossRef
  • Proton beam therapy in the management of hepatocellular carcinoma
    Kenneth S. H. Chok, Tiffany Y. T. Joeng, Darren M. C. Poon
    Expert Review of Gastroenterology & Hepatology.2025; 19(5): 495.     CrossRef
  • Micro-Nano Convergence-Driven Radiotheranostic Revolution in Hepatocellular Carcinoma
    Yisheng Peng, Hui Liu, Mengmeng Miao, Xu Cheng, Shangqing Chen, Kaifei Yan, Jing Mu, Hongwei Cheng, Gang Liu
    ACS Applied Materials & Interfaces.2025; 17(20): 29047.     CrossRef
  • Combination of radiotherapy and ICIs in advanced hepatocellular carcinoma: A systematic review of current evidence and future prospects (Review)
    Cheng Ma, Xinlin Yu, Xialin Zhang, Lihong Su, Ou Jiang, Ran Cui
    Oncology Letters.2025; 30(1): 1.     CrossRef
  • Multidisciplinary strategies including local treatment to achieve drug‑free status after atezolizumab plus bevacizumab treatment in hepatocellular carcinoma
    Nobuaki Ishihara, Shohei Komatsu, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Yuzo Kodama, Takumi Fukumoto
    Oncology Letters.2025; 30(4): 1.     CrossRef
  • Proton Beam Therapy Provides Longer Survival and Preserves Muscle Mass in Hepatocellular Carcinoma Compared to TACE+RFA
    Takuto Nosaka, Ryotaro Sugata, Yosuke Murata, Yu Akazawa, Tomoko Tanaka, Kazuto Takahashi, Tatsushi Naito, Masahiro Ohtani, Kenji Takata, Tetsuya Tsujikawa, Yoshitaka Sato, Yoshikazu Maeda, Hiroyasu Tamamura, Yasunari Nakamoto
    Cancers.2025; 17(17): 2849.     CrossRef
  • Current application status of proton beam therapy for gastrointestinal tumors
    Jingwen Zhang, Han Zhou, Benxin Zhao, Tian Liu, Chang Guo, Wenjing Fei, Zetian Shen
    Oncologie.2025; 27(6): 855.     CrossRef
  • A contrast‑enhanced CT histogram‑driven nomogram for predicting post‑radiotherapy liver regeneration in hepatocellular carcinoma
    Bo Liu, Yuan Xu, Xijie Zhang, Wei Qi, Bo Ren, Wenjia Kong, Wence Zhou
    Radiation Oncology.2025;[Epub]     CrossRef
  • Highly permeable and tumor-selective killing Doxil for efficient cancer therapy
    Yidan Shen, Yiyang Sun, Yangla Xie, Yanpeng Liu, Zile Shao, Siyu Chen, Zhengxing Lian, Chang Xu, Fei Lv, Jinyi Tong, Youqing Shen, Nasha Qiu
    Nano Research.2025; 18(12): 94907987.     CrossRef
  • The Rac1-USP11 feedback amplification loop: a radiation-activated engine driving radioresistance in hepatocellular carcinoma
    Kaixiao Zhou, Yabo Jiang, Jiahao Guo, Haobo Zhang, Yuhao Hu, Xuanyu Meng, Yecheng Li, Shaohua Wei, Jian Wang, Xubiao Wei, Shuqun Cheng, Jianping Cao, Yang Jiao
    British Journal of Cancer.2025;[Epub]     CrossRef
  • Intrahepatic IgA complex induces polarization of cancer-associated fibroblasts to matrix phenotypes in the tumor microenvironment of HCC
    Jong Geun Park, Pu Reun Roh, Min Woo Kang, Sung Woo Cho, Suhyun Hwangbo, Hae Deok Jung, Hyun Uk Kim, Ji Hoon Kim, Jae-Sung Yoo, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Young Kyoung You, Ho Joong Choi, Jae Yong Ryu, Pil Soo Sung
    Hepatology.2024; 80(5): 1074.     CrossRef
  • Clinical outcomes and safety of external beam radiotherapy with extensive intrahepatic targets for advanced hepatocellular carcinoma: A single institutional clinical experience
    Sunmin Park, Chai Hong Rim, Won Sup Yoon
    Saudi Journal of Gastroenterology.2024; 30(6): 399.     CrossRef
  • Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy
    Sang Min Yoon
    Clinical and Molecular Hepatology.2023; 29(4): 977.     CrossRef
  • 10,337 View
  • 188 Download
  • 17 Web of Science
  • Crossref

Hepatic neoplasm

Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma
Hwa Kyung Byun, Changhwan Kim, Jinsil Seong
Clin Mol Hepatol 2023;29(4):945-957.
Published online August 14, 2023
DOI: https://doi.org/10.3350/cmh.2023.0217
Hepatocellular carcinoma (HCC) is a highly lethal cancer with limited treatment options and poor prognosis. Carbon ion radiotherapy (CIRT) has emerged as a promising treatment modality for HCC due to its unique physical and biological properties. CIRT uses carbon ions to target and destroy cancer cells with a high precision and efficacy. The Bragg Peak phenomenon allows precise dose delivery to the tumor while minimizing damage to healthy tissues. In addition, the high relative biological effectiveness of carbon ions can be shown against radioresistant and hypoxic tumor areas. CIRT also offers a shorter treatment schedule than conventional radiotherapy, which increases patient convenience and compliance. The clinical outcomes of CIRT for HCC have shown excellent local control rates with minimal side effects. Considering its physical and biological properties, CIRT may be a viable option for complex clinical scenarios such as patients with poor liver function, large tumors, re-irradiation cases, and tumors close to critical organs. Further research and larger studies are needed to establish definitive indications for CIRT and to compare its efficacy with that of other treatment modalities. Nevertheless, CIRT offers a potential breakthrough in HCC management, providing hope for improved therapeutic outcomes and reduced treatment-related toxicities.

Citations

Citations to this article as recorded by  Crossref logo
  • Comparison of Prognostic Outcomes Between Repeat Liver Resection and Particle Therapy for Patients with Recurrent Hepatocellular Carcinoma
    Tatsuki Kusuhara, Hidetoshi Gon, Kazuki Terashima, Shohei Komatsu, Yoshiro Matsuo, Sunao Tokumaru, Hirochika Toyama, Masahiro Kido, Tomoaki Okimoto, Takumi Fukumoto
    Annals of Surgical Oncology.2025; 32(2): 1073.     CrossRef
  • Tumor‐Targeted Catalytic Immunotherapy
    En‐Li Yang, Wu‐Yin Wang, Ying‐Qi Liu, Hong Yi, Aiwen Lei, Zhi‐Jun Sun
    Advanced Materials.2025;[Epub]     CrossRef
  • Validation study on accuracy of our newly proposed methods for post-therapeutic liver reserve capacity estimation utilizing 99 mTc-GSA scintigraphy prior to carbon-ion radiotherapy
    Kana Yamazaki, Tatsuya Higashi, Ryuichi Nishii, Tamasa Terada, Yoichi Mizutani, Yuki Ogura, Mana Akamatsu, Toshitaka Kuroiwa, Hirokazu Makishima, Masaru Wakatsuki, Hitoshi Ishikawa
    Annals of Nuclear Medicine.2025; 39(8): 781.     CrossRef
  • Study on the application of multislice spiral CT in the diagnosis and evaluation of radiotherapy efficacy for esophageal cancer
    W. Huang, L. Wang, H. Ye
    International Journal of Radiation Research.2025; 23(1): 121.     CrossRef
  • Cost-Effectiveness of Carbon Ion Radiotherapy in Oncology: A Systematic Review
    Abdulrahman Bin Sumaida, Nandan M Shanbhag, Khalifa AlKaabi, Khalid Balaraj
    Cureus.2025;[Epub]     CrossRef
  • First report of metabolic complete response in hepatic sarcomatoid carcinoma achieved with carbon-ion radiotherapy
    Ryu Takakura, Yoshiyuki Ota, Yuki Yamazaki, Satoru Iwamoto, Koki Kurouchi, Koki Moriyoshi, Shin’ichi Miyamoto
    Clinical Journal of Gastroenterology.2025; 18(5): 879.     CrossRef
  • Advances in radiotherapy for mouth neoplasms: emerging technologies and future perspectives
    Xuhong Liu, Zhuoya Zhang, Xinyu Deng, Zekun Lang, Jianrong Wang
    Discover Oncology.2025;[Epub]     CrossRef
  • Adverse Events After Carbon-Ion Radiotherapy (CIRT) for Hepatocellular Carcinoma and Risk Factors for Biliary Stricture After CIRT: A Retrospective Study
    Keita Maki, Hiroaki Haga, Tomohiro Katsumi, Kyoko Hoshikawa, Fumiya Suzuki, Fumi Uchiyama, Takashi Kaneko, Masashi Koto, Yoshiyuki Ueno
    Cancers.2025; 17(15): 2542.     CrossRef
  • Treatment Outcomes in Patients Receiving Carbon-Ion Radiotherapy Versus Hepatectomy for Hepatocellular Carcinoma (≥4 cm): A Retrospective Study in Japan
    Keita Maki, Hiroaki Haga, Tomohiro Katsumi, Kyoko Hoshikawa, Takashi Kaneko, Ryosuke Takahashi, Shuichiro Sugawara, Masashi Koto, Fuyuhiko Motoi, Yoshiyuki Ueno
    Journal of Clinical Medicine.2025; 14(16): 5678.     CrossRef
  • Carbon-Ion Radiotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects: A Narrative Review
    Reina Sasaki-Tanaka, Hiroyuki Abe, Tomoaki Yoshida, Yusuke Watanabe, Naruhiro Kimura, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Kenya Kamimura, Tatsuo Kanda, Shuji Terai
    Journal of Clinical Medicine.2025; 14(17): 6107.     CrossRef
  • Carbon-ion radiotherapy induces ferroptosis and M1 macrophage polarization to inhibit the development of gastric cancer by downregulating DHODH
    Yue Wang, Hongyi Cai
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • A multi‐modal diffusion model for noise reduction of particle number limited Monte Carlo dose calculation for carbon ion radiotherapy
    Jueye Zhang, Youfang Lai, Haonan Feng, Xiangde Luo, Kai‐Wen Li, Tenghui Wang, Cheng Chang, Gen Yang, Chen Lin, Tian Li, Chao Yang, Yibao Zhang
    Medical Physics.2025;[Epub]     CrossRef
  • Targeting gut microbiota and metabolites in cancer radiotherapy
    Shuling Ma, Xinpei Li, Shijie Shang, Zijun Zhai, Meng Wu, Qian Song, Dawei Chen
    Clinical and Translational Medicine.2025;[Epub]     CrossRef
  • Potential applications of metal-based nanomaterials in tumor radiotherapy: from x-ray to particle therapies
    Yingxin Liu, Butuo Li, Linlin Wang
    Cancer Nanotechnology.2025;[Epub]     CrossRef
  • The research perspectives and frontiers on radiotherapy for hepatocellular carcinoma: a bibliometric analysis and systematic review
    Tao He, Hong Xiao, Bin Yi, Chengyan Zhou, Juan Yang, Ke Sun, Jieyu Zou
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Metronidazole-modified Au@BSA nanocomposites for dual sensitization of radiotherapy in solid tumors
    Qijun Du, Ho-Yin Yuen, Jingke Pan, Chenwei Sun, Di Wu, Jie Liu, Guohua Wu, Xin Zhao, Shuqi Wang
    Journal of Materials Chemistry B.2024; 12(38): 9686.     CrossRef
  • Value of Carbon-Ion Radiation Therapy for Breast Cancer
    Bowen Yu, Kai-Wen Li, Yingyi Fan, Xiaohua Pei
    International Journal of Particle Therapy.2024; 14: 100629.     CrossRef
  • Advances in external beam radiation for hepatocellular carcinoma, stereotactic body radiation therapy (SBRT) and particle therapy
    Lokesh Seth, Kevin L. Stephans
    Hepatoma Research.2024;[Epub]     CrossRef
  • Mechanisms of Cancer Cell Radioresistance: Modern Trends and Research Prospects
    M. G Sharapov, E. E Karmanova, S. V Gudkov
    Biofizika.2024; 69(6): 1235.     CrossRef
  • Mechanisms of Cancer Cell Radioresistance: Modern Trends and Research Prospects
    M. G. Sharapov, E. E. Karmanova, S. V. Gudkov
    Biophysics.2024; 69(6): 1064.     CrossRef
  • Biological and clinical significance of radiomics features obtained from magnetic resonance imaging preceding pre-carbon ion radiotherapy in prostate cancer based on radiometabolomics
    Guangyuan Zhang, Zhenshan Zhang, Yulei Pei, Wei Hu, Yushan Xue, Renli Ning, Xiaomao Guo, Yun Sun, Qing Zhang
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Novel paradigm in the treatment of hepatocellular carcinoma: Anticipating breakthroughs with particle therapy
    Sang Min Yoon
    Clinical and Molecular Hepatology.2023; 29(4): 977.     CrossRef
  • Pencil Beam Scanning Carbon Ion Radiotherapy for Hepatocellular Carcinoma
    Wenna Zhang, Xin Cai, Jiayao Sun, Weiwei Wang, Jingfang Zhao, Qing Zhang, Guoliang Jiang, Zheng Wang
    Journal of Hepatocellular Carcinoma.2023; Volume 10: 2397.     CrossRef
  • 8,422 View
  • 138 Download
  • 21 Web of Science
  • Crossref

Original Articles

Hepatic neoplasm

Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study
Gyu Sang Yoo, Won-Gyun Ahn, Shin-Yeong Kim, Wonseok Kang, Changhoon Choi, Hee Chul Park
Clin Mol Hepatol 2021;27(1):144-156.
Published online December 7, 2020
DOI: https://doi.org/10.3350/cmh.2020.0095
Background/Aims
The abscopal effect, a rare phenomenon induced by radiation, can be reinforced by immunotherapy. Although radiation therapy and immunotherapy are increasingly being utilized for the treatment of hepatocellular carcinoma (HCC), whether immunotherapy could boost the abscopal effect remains unclear. In this study, we aimed to elucidate the immunological mechanisms underlying the abscopal effect induced by the combination of irradiation and immunotherapy in a murine HCC model.
Methods
A syngeneic HCC mouse model was established by transplanting murine Hepa 1–6 HCC cells into both hind legs of immunocompetent C57BL/6 mice. The tumors on the right hind legs were irradiated, and abscopal effects were observed in the non-irradiated tumors on the left hind leg with or without the coadministration of anti-programmed cell death 1 (PD-1) antibodies. Flow cytometric analyses were performed to analyze the distributions of immune cells infiltrating both irradiated and non-irradiated tumors and the tumor-draining lymph nodes (TDLNs).
Results
Administration of 16 Gy in two fractions more effectively inhibited the growth of both irradiated and nonirradiated tumors with higher tumor infiltration of cytotoxic T cells than 8 Gy did in a single fraction. The higher dose also increased activated dendritic cells in TDLNs, which had higher expression of the programmed cell death ligand 1. Coadministration of anti-PD-1 antibodies significantly enhanced the abscopal effect and increased infiltration of activated cytotoxic T cells in both irradiated and non-irradiated tumors.
Conclusions
Our findings show that adding anti-PD-1 therapy to radiation enhanced the abscopal effect in a syngeneic murine model of HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Immune microenvironment and immunotherapy in hepatocellular carcinoma: mechanisms and advances
    Dong Xie, Yang Liu, Fangbiao Xu, Zhibo Dang, Mengge Li, Qinsheng Zhang, Zhongqin Dang
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Radiosensitization strategies for hepatocellular carcinoma: Mechanisms, therapeutic advances, and clinical perspectives
    Jiahui Yang, Rong Chen
    Critical Reviews in Oncology/Hematology.2025; 213: 104773.     CrossRef
  • Stereotactic body radiation therapy (SBRT) increases anti-PD-1 antitumor activity by enhancing the tumor immune microenvironment in mice with metastatic hepatocellular carcinoma
    Ke Xu, Tao Gu, Ke Su, Xin Liu, Bingsheng He, Jie He, Hao Chi, Xuancheng Zhou, Hanlin Liu, Rui Xiao, Xue Tang, Qinni Ye, Xue Zhou, Yingpeng Liu, Jie Xiong, Pan Wang, Han Li, Kun He, Lu Guo, Yunwei Han
    Discover Oncology.2025;[Epub]     CrossRef
  • Sorafenib with or without co-interventions for hepatocellular carcinoma
    Shanshan Chen, Jian Ping Liu, Xinyu Li, Shoutao Dang, Wei Li
    Cochrane Database of Systematic Reviews.2025;[Epub]     CrossRef
  • Recent Advances in Combination Therapy of YAP Inhibitors with Physical Anti-Cancer Strategies
    Junchi Zhou, Changyan Yu, Wanhong Yang, Nian Jiang, Sanhua Li, Yun Liu, Xinting Zhu
    Biomolecules.2025; 15(7): 945.     CrossRef
  • Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma
    Brandon M. Meyers, Howard J. Lim, Mayur Brahmania, Dave M. Liu, Vincent C. Tam, Deanna McLeod, Ravi Ramjeesingh, Jennifer J. Knox, Arndt Vogel
    Therapeutic Advances in Medical Oncology.2025;[Epub]     CrossRef
  • Synergies between radiotherapy and immunotherapy: a systematic review from mechanism to clinical application
    JingLong Jiang, HouZe Li, QingCui Ma, Jing Liu, Fu Ren, YingQiu Song, TianLu Wang, KeYan Li, Ning Li
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma
    Xiangqi Chen, Mingjian Piao, Zixiang Zhou, Shanshan Wang, Shuofeng Li, Nan Zhang, Boyu Sun, Kai Liu, Xu Yang, Xiaobo Yang, Xiaohua Shi, Chengpei Zhu, Haitao Zhao
    Cancer Immunology, Immunotherapy.2025;[Epub]     CrossRef
  • Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer
    Xiangqi Chen, Zixiang Zhou, Shuofeng Li, Guanhua Yu, Shi Feng, Ze Zhou, Boyu Sun, Shanshan Wang, Kai Liu, Chengjie Li, Mingjian Piao, Mingming Wang, Yihong Zhang, Hu Li, Chengpei Zhu, Zhenyu Zhu, Haitao Zhao
    Cancer Immunology, Immunotherapy.2025;[Epub]     CrossRef
  • Molecular mechanisms underlying the abscopal effect induced by radiotherapy and its synergistic translational potential with immunotherapy
    Xinyi Chen, Mu Yang, Yongbiao Huang, Jingyao Tu, Yuwen Cai, Xianglin Yuan
    Therapeutic Advances in Medical Oncology.2025;[Epub]     CrossRef
  • Hepatocellular Carcinoma Showing Tumor Shrinkage Due to an Abscopal Effect
    Ryo Yano, Masashi Hirooka, Makoto Morita, Yuki Okazaki, Yoshiko Nakamura, Yusuke Imai, Takao Watanabe, Yohei Koizumi, Osamu Yoshida, Yoshio Tokumoto, Masanori Abe, Yoichi Hiasa
    Internal Medicine.2024; 63(2): 241.     CrossRef
  • Multidisciplinary treatment for patients with advanced hepatocellular carcinoma complicated by Vp4 portal vein tumor thrombosis: Combination of atezolizumab and bevacizumab after hepatic arterial infusion chemotherapy and radiotherapy: A case series
    Kenji Yamaoka, Tomokazu Kawaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Takashi Nakahara, Atsushi Ohno, Eisuke Murakami, Daiki Miki, Masataka Tsuge, Keigo Chosa, Kazuo Awai, Junichi Hirokawa, Yasushi Nagata, Shiro Oka
    Medicine: Case Reports and Study Protocols.2024; 5(6): e00325.     CrossRef
  • Enhancing Magnetic Hyperthermia Efficacy through Targeted Heat Shock Protein 90 Inhibition: Unveiling Immune-Mediated Therapeutic Synergy in Glioma Treatment
    Ruby Gupta, Anjali Chauhan, Tashmeen Kaur, Bijoy Kumar Kuanr, Deepika Sharma
    ACS Nano.2024; 18(26): 17145.     CrossRef
  • Lymphatic system regulation of anti-cancer immunity and metastasis
    Pin-Ji Lei, Cameron Fraser, Dennis Jones, Jessalyn M. Ubellacker, Timothy P. Padera
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Research Progress on Dendritic Cells in Hepatocellular Carcinoma Immune Microenvironments
    Wenya Li, Guojie Chen, Hailin Peng, Qingfang Zhang, Dengyun Nie, Ting Guo, Yinxing Zhu, Yuhan Zhang, Mei Lin
    Biomolecules.2024; 14(9): 1161.     CrossRef
  • Evaluation of Treatments with Radiotherapy Alone and Radiotherapy Plus Chemo-immunotherapy in Patients with Primary Liver Cancer based on Blood Biomarkers
    Shigao Huang, Yutian Yin, Jianping Li, Mei Shi, Huijie Bian, Lina Zhao
    Current Medicinal Chemistry.2024; 31(40): 6586.     CrossRef
  • Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact
    Reham M. M. El-Hazek, Nashwa H. Zaher, Mostafa G. M. El-Gazzar, Noha A. Fadel, Walaa A. El-Sabbagh
    Scientific Reports.2023;[Epub]     CrossRef
  • The paradoxical role of radiation‐induced cGAS–STING signalling network in tumour immunity
    Xiaoyi Zhang, Han Zhang, Jiajia Zhang, Mengdie Yang, Mengqin Zhu, Yuzhen Yin, Xin Fan, Fei Yu
    Immunology.2023; 168(3): 375.     CrossRef
  • Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis
    Quan Wang, Xiaoquan Ji, Jing Sun, Wengang Li, Xuezhang Duan, Aimin Zhang
    Journal of Cancer Research and Clinical Oncology.2023; 149(10): 7441.     CrossRef
  • Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy
    Marzieh Nikoo, Zahraa F. Hassan, Mahsa Mardasi, Elmira Rostamnezhad, Fatemeh Roozbahani, Sahel Rahimi, Javad Mohammadi
    Pathology - Research and Practice.2023; 247: 154473.     CrossRef
  • Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma
    Alexander H. Shannon, Ashish Manne, Dayssy A. Diaz Pardo, Timothy M. Pawlik
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma
    Perla Chami, Youssef Diab, Danny N. Khalil, Hassan Azhari, William R. Jarnagin, Ghassan K. Abou-Alfa, James J. Harding, Joseph Hajj, Jennifer Ma, Maria El Homsi, Marsha Reyngold, Christopher Crane, Carla Hajj
    International Journal of Molecular Sciences.2023; 24(23): 16773.     CrossRef
  • Inducing the Abscopal Effect in Liver Cancer Treatment: The Impact of Microwave Ablation Power Levels and PD-1 Antibody Therapy
    Changli Liao, Guiyuan Zhang, Ruotong Huang, Linyuan Zeng, Bin Chen, Haitao Dai, Keyu Tang, Run Lin, Yonghui Huang
    Pharmaceuticals.2023; 16(12): 1672.     CrossRef
  • Prognostic significance of albumin–bilirubin score in patients with unresectable hepatocellular carcinoma undergoing combined immunotherapy and radiotherapy
    Dezuo Dong, Xianggao Zhu, Hongzhi Wang, Lijuan Li, Meng Wan, Shuai Li, Yangzi Zhang, Jianhao Geng, Yongheng Li, Weihu Wang
    Journal of Medical Imaging and Radiation Oncology.2022; 66(5): 662.     CrossRef
  • Neoadjuvant Approaches in Hepatocellular Carcinoma: There's No Time Like the Present
    Joseph W. Franses, Andrew X. Zhu
    Clinical Cancer Research.2022; 28(13): 2738.     CrossRef
  • Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma
    Pil Soo Sung
    Clinical and Molecular Hepatology.2022; 28(3): 333.     CrossRef
  • Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial
    Jian-Xu Li, Ting-Shi Su, Wen-Feng Gong, Jian-Hong Zhong, Liu-Ying Yan, Jie Zhang, Li-Qing Li, Mei-Ling He, Rui-Jun Zhang, You-Qin Du, Xiao-Ting Wang, Shi-Xiong Liang, Bang-De Xiang
    Hepatology International.2022; 16(5): 1179.     CrossRef
  • PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
    Qian Li, Jingjing Han, Yonglin Yang, Yu Chen
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • An Abscopal Effect in a Gastric Cancer Patient Treated with Combined Chemoimmunotherapy and Palliative Radiotherapy
    Zengtao Bao, Qiang Tang, Huiyu Chen, Baoming Zhang, Wenchao Shi, Dezhi Gu
    Immunotherapy.2022; 14(18): 1429.     CrossRef
  • Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma
    Jun Won Kim, Ik Jae Lee
    Clinical and Molecular Hepatology.2021; 27(1): 103.     CrossRef
  • Manganese Ferrite Nanoparticles Enhance the Sensitivity of Hepa1-6 Hepatocellular Carcinoma to Radiation by Remodeling Tumor Microenvironments
    Sung-Won Shin, Kyungmi Yang, Miso Lee, Jiyoung Moon, Arang Son, Yeeun Kim, Suha Choi, Do-hyung Kim, Changhoon Choi, Nohyun Lee, Hee Chul Park
    International Journal of Molecular Sciences.2021; 22(5): 2637.     CrossRef
  • Immunogenic Cell Death Induction by Ionizing Radiation
    Mengqin Zhu, Mengdie Yang, Jiajia Zhang, Yuzhen Yin, Xin Fan, Yu Zhang, Shanshan Qin, Han Zhang, Fei Yu
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Current role of proton beam therapy in patients with hepatocellular carcinoma
    Gyu Sang Yoo, Jeong Il Yu, Hee Chul Park
    International Journal of Gastrointestinal Intervention.2021; 10(4): 175.     CrossRef
  • Antigen-Capturing Mesoporous Silica Nanoparticles Enhance the Radiation-Induced Abscopal Effect in Murine Hepatocellular Carcinoma Hepa1-6 Models
    Kyungmi Yang, Changhoon Choi, Hayeong Cho, Won-Gyun Ahn, Shin-Yeong Kim, Sung-Won Shin, Yeeun Kim, Taekyu Jang, Nohyun Lee, Hee Chul Park
    Pharmaceutics.2021; 13(11): 1811.     CrossRef
  • 11,884 View
  • 331 Download
  • 32 Web of Science
  • Crossref

Hepatic neoplasm

Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial
Sang Min Yoon, So Yeon Kim, Young-Suk Lim, Kang Mo Kim, Ju Hyun Shim, Danbi Lee, Jihyun An, Jinhong Jung, Jong Hoon Kim, Han Chu Lee
Clin Mol Hepatol 2020;26(4):506-515.
Published online July 10, 2020
DOI: https://doi.org/10.3350/cmh.2020.0038
Background/Aims
Stereotactic body radiation therapy (SBRT) is used as an alternative ablative treatment in patients with hepatocellular carcinoma (HCC) not suitable for curative treatments. The purpose of this prospective study was to evaluate the long-term efficacy of SBRT for small (≤5 cm) HCCs.
Methods
A phase II, single-arm clinical trial on SBRT for small HCCs was conducted at an academic tertiary care center. The planned SBRT dose was 45 Gy with a fraction size of 15-Gy over 3 consecutive days. The primary endpoint was 2-year local control rate. Radiologic responses were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) and the modified RECIST criteria.
Results
Between 2013 and 2016, 50 patients (53 lesions) were enrolled, with a median follow-up period of 47.8 months (range, 2.9–70.6). Patients’ age ranged from 41 to 74 years, and 80% were male. Median tumor size was 1.3 cm (range, 0.7–3.1). The 2- and 5-year local control rates were 100% and 97.1%, respectively. The 5-year overall survival rate was 77.6%. Six months after SBRT, radiologic responses were evident in 44 lesions (83%) according to the RECIST criteria and 49 (92.4%) according to the modified RECIST criteria. None of the patients showed grade ≥3 adverse events.
Conclusions
SBRT showed excellent results as an ablative treatment for patients with small HCCs while showing minimal toxicities. SBRT can be a good alternative for both curative and salvage intents in patients with HCCs that are unsuitable for curative treatments.

Citations

Citations to this article as recorded by  Crossref logo
  • Exploring the Evolving Landscape of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma
    Deepti Sharma, Divya Khosla, Babu L. Meena, Hanuman P. Yadav, Rakesh Kapoor
    Journal of Clinical and Experimental Hepatology.2025; 15(1): 102386.     CrossRef
  • Stereotactic body radiotherapy alone versus stereotactic body radiotherapy after incomplete transarterial therapy for hepatocellular carcinoma
    Youngju Song, Jinhong Jung, Jin‐hong Park, So Yeon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Sang Min Yoon
    Journal of Medical Imaging and Radiation Oncology.2025; 69(1): 144.     CrossRef
  • Comparison of stereotactic body radiotherapy and transcatheter arterial chemoembolization for hepatocellular carcinoma: Systematic review and meta‐analysis
    Satoshi Komiyama, Atsuya Takeda, Yudai Tateishi, Yuichiro Tsurugai, Takahisa Eriguchi, Nobuyuki Horita
    Radiotherapy and Oncology.2025; 202: 110614.     CrossRef
  • Development and Validation of a Prediction Model for Cardiac Events in Patients With Hepatocellular Carcinoma Undergoing Stereotactic Body Radiation Therapy
    Hye In Lee, Jaeman Son, Byungchul Cho, Youngmoon Goh, Jinhong Jung, Jin-hong Park, Eui Kyu Chie, Kyung Su Kim, Young-Hak Kim, Hyun-Cheol Kang, Sang Min Yoon
    International Journal of Radiation Oncology*Biology*Physics.2025; 122(5): 1272.     CrossRef
  • Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
    Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S228.     CrossRef
  • Proton beam therapy in the management of hepatocellular carcinoma
    Kenneth S. H. Chok, Tiffany Y. T. Joeng, Darren M. C. Poon
    Expert Review of Gastroenterology & Hepatology.2025; 19(5): 495.     CrossRef
  • Modern approach to hepatocellular carcinoma treatment
    Francesco Cortese, Fotis Anagnostopoulos, Maria Vittoria Bazzocchi, Silvio Caringi, Antonio Rosario Pisani, Matteo Renzulli, Ioannis Paraskevopoulos, Letizia Laera, Alessia Surgo, Stavros Spiliopoulos, Riccardo Memeo, Riccardo Inchingolo
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Dynamic Tumor Tracking (DTT) for Hepatocellular Carcinoma Using the Vero4DRT Gimbaled Linac Stereotactic Body Radiation Therapy (SBRT) System
    Ronan L. McDermott, Emma M. Dunne, Lok In Josephine Ma, Alanah M Bergman, Marie-Laure A. Camborde, Tania Karan, Ante Mestrovic, Emilie E. Carpentier, Mitchell C. C. Liu, Devin Schellenberg, Roy M. K. Ma
    Cancers.2025; 17(17): 2926.     CrossRef
  • Stereotactic hepatic radiation therapy and immunotherapy in hepatocellular carcinoma
    Carmen Cañadillas Navero, Íñigo San Miguel Arregui, Luis Alberto Pérez Romasanta
    Revisiones en Cáncer.2025;[Epub]     CrossRef
  • China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)
    Jian Zhou, Huichuan Sun, Zheng Wang, Wenming Cong, Mengsu Zeng, Weiping Zhou, Lianxin Liu, Tianfu Wen, Ming Kuang, Bixiang Zhang, Kaishan Tao, Guohong Han, Zhiping Yan, Maoqiang Wang, Ruibao Liu, Jinhe Guo, Zhaochong Zeng, Ping Liang, Zhenggang Ren, Jinli
    Liver Cancer.2025; : 1.     CrossRef
  • The #HOPE4LIVER Single-arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors
    Timothy J. Ziemlewicz, Jeffrey J. Critchfield, Mishal Mendiratta-Lala, Philipp Wiggermann, Maciej Pech, Xavier Serres-Créixams, Meghan Lubner, Tze Min Wah, Peter Littler, Clifford R. Davis, Govindarajan Narayanan, Sarah B. White, Osman Ahmed, Zach S. Coll
    Annals of Surgery.2025; 282(6): 908.     CrossRef
  • Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines
    Sun Hyun Bae, Seok-Joo Chun, Joo-Hyun Chung, Eunji Kim, Jin-Kyu Kang, Won Il Jang, Ji Eun Moon, Isaure Roquette, Xavier Mirabel, Tomoki Kimura, Masayuki Ueno, Ting-Shi Su, Alison C. Tree, Matthias Guckenberger, Simon S. Lo, Marta Scorsetti, Ben J. Slotman
    International Journal of Radiation Oncology*Biology*Physics.2024; 118(2): 337.     CrossRef
  • Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study
    Bo Hyun Kim, Hee Chul Park, Tae Hyun Kim, Young-Hwan Koh, Jung Yong Hong, Yuri Cho, Dong Hyun Sinn, Boram Park, Joong-Won Park
    JHEP Reports.2024; 6(4): 100991.     CrossRef
  • Chemoembolization versus Radiotherapy for Single Hepatocellular Carcinomas of ≤3 cm Unsuitable for Image-Guided Tumor Ablation
    Jihye Lim, Euichang Kim, Sehee Kim, So Yeon Kim, Jin Hyoung Kim, Sang Min Yoon, Ju Hyun Shim
    Gut and Liver.2024; 18(1): 125.     CrossRef
  • Canine primary liver tumors treated with stereotactic body radiation therapy: A case series
    Qiao Ying Pauline Chan, Deanna Morrow, David Lurie
    Veterinary Radiology & Ultrasound.2024; 65(2): 121.     CrossRef
  • Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma
    Feng Liu, Doris R. Brown, Michael T. Munley
    Radiotherapy and Oncology.2024; 194: 110223.     CrossRef
  • Stereotactic body radiation therapy in patients with centrally located hepatocellular carcinoma: A retrospective, single-arm, multi-center study
    Dan-Xue Zheng, Yi-Xing Chen, Jing Sun, Yong Hu, Ping Yang, Yang Zhang, Xue-Zhang Duan, Zhao-Chong Zeng
    Clinical and Translational Radiation Oncology.2024; 46: 100767.     CrossRef
  • Dynamic liver volume change in predicting hepatic decompensation and long‐term effects of stereotactic body radiation therapy
    Sumin Lee, Jonggi Choi, Jin‐hong Park, Chae Yeon Lim, Eunyeong Yang, Sang Min Yoon, Jinhong Jung
    Journal of Gastroenterology and Hepatology.2024; 39(8): 1648.     CrossRef
  • Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC ≤5.0 cm
    Zhoutian Yang, Shiliang Liu, Li Hu, Jinbin Chen, Juncheng Wang, Yangxun Pan, Li Xu, Mengzhong Liu, Minshan Chen, Mian Xi, Yaojun Zhang
    JHEP Reports.2024; 6(10): 101151.     CrossRef
  • Clinical outcomes and safety of external beam radiotherapy with extensive intrahepatic targets for advanced hepatocellular carcinoma: A single institutional clinical experience
    Sunmin Park, Chai Hong Rim, Won Sup Yoon
    Saudi Journal of Gastroenterology.2024; 30(6): 399.     CrossRef
  • Long-term outcomes of more than a decade treating patients with stereotactic body radiation therapy for hepatocellular carcinoma
    Wilhelm den Toom, Eva M. Negenman, Francois E.J.A. Willemssen, Erik van Werkhoven, Robert J. Porte, Roeland F. de Wilde, Dave Sprengers, Imogeen E. Antonisse, Ben J.M. Heijmen, Alejandra Méndez Romero
    Clinical and Translational Radiation Oncology.2024; 49: 100878.     CrossRef
  • Long-Term Outcome of a Multicenter Prospective Study on Efficacy and Safety of High-Dose Stereotactic Body Radiation Therapy ≥48-h Interfraction Interval for ≤5 cm Hepatocellular Carcinoma
    Jin-Kyu Kang, Mi-Sook Kim, Won Il Jang, Chul Ju Han, Jin Kim, Su Cheol Park, Young-Joo Shin, Chul Won Choi, Wan Jeon, Tosol Yu, Ah Ram Chang, Hae Jin Park, Younghee Park, Eun Seog Kim, Sunmi Jo, Woo Chul Kim, Hun Jung Kim, Sun Hyun Bae, Eunji Kim
    Liver Cancer.2024; 14(3): 248.     CrossRef
  • Advances in external beam radiation for hepatocellular carcinoma, stereotactic body radiation therapy (SBRT) and particle therapy
    Lokesh Seth, Kevin L. Stephans
    Hepatoma Research.2024;[Epub]     CrossRef
  • Therapeutic Outcome of Stereotactic Body Radiotherapy for Small Hepatocellular Carcinoma Lesions – A Systematic Review and Network Meta-analysis
    L.-Q. Li, T.-S. Su, Q.-Y. Wu, Z.-T. Lin, S.-X. Liang
    Clinical Oncology.2023; 35(10): 652.     CrossRef
  • Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2023; 107: 66.     CrossRef
  • Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview
    Yukinori Matsuo
    Current Oncology.2023; 30(2): 2493.     CrossRef
  • Advances in Radiation Therapy for Primary Liver Cancer
    Kyle C. Cuneo, Daniel J. Herr
    Surgical Oncology Clinics of North America.2023; 32(3): 415.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Journal of Liver Cancer.2023; 23(1): 1.     CrossRef
  • Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis
    Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi,
    Hepatology.2023; 77(5): 1746.     CrossRef
  • Stereotactic Body Radiation Therapy versus Surgical Resection for Stage I/II Hepatocellular Carcinoma
    Emrullah Birgin, Svetlana Hetjens, Moses Tam, Camilo Correa-Gallego, Nuh N. Rahbari
    Cancers.2023; 15(8): 2330.     CrossRef
  • Clinical impact of carbon‐ion radiotherapy on hepatocellular carcinoma with Child‐Pugh B cirrhosis
    Yuichi Hiroshima, Masaru Wakatsuki, Takashi Kaneko, Hirokazu Makishima, Naomi Nagatake Okada, Shigeo Yasuda, Hitoshi Ishikawa, Hiroshi Tsuji
    Cancer Medicine.2023; 12(13): 14004.     CrossRef
  • Local Therapies for Hepatocellular Carcinoma and Role of MRI-Guided Adaptive Radiation Therapy
    Yirong Liu, Brian Chou, Amulya Yalamanchili, Sara N. Lim, Laura A. Dawson, Tarita O. Thomas
    Journal of Clinical Medicine.2023; 12(10): 3517.     CrossRef
  • Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
    Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2023; 29(3): 593.     CrossRef
  • Impact of radiation therapy and alpha-fetoprotein level on survival outcomes for patients with hepatocellular carcinoma: A population-based study
    Yahong Chen, Xueqing Yang, Xiawei Li
    Clinics and Research in Hepatology and Gastroenterology.2023; 47(8): 102196.     CrossRef
  • Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis
    Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim
    Clinical and Molecular Hepatology.2023; 29(4): 1013.     CrossRef
  • Large hepatocellular carcinoma treated with sequential SBRT and immunotherapy with anti-VEGF (Vascular Endothelial Growth Factor) therapy
    Bardia Bidarmaghz, Marwan Idrees, Yoo Young Lee, Peter Hodgkinson
    BMJ Case Reports.2023; 16(12): e256931.     CrossRef
  • Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL
    Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(2): 288.     CrossRef
  • Stereotactic body radiation therapy for primary liver tumors: An effective liver‐directed therapy in the toolbox
    Hannah J. Roberts, Jennifer Y. Wo
    Cancer.2022; 128(5): 956.     CrossRef
  • External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2022; 14(3): 711.     CrossRef
  • Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients
    Sumin Lee, Jinhong Jung, Jin-hong Park, So Yeon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Hee Hyun Park, Jong Hoon Kim, Sang Min Yoon
    BMC Cancer.2022;[Epub]     CrossRef
  • Hypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size
    S. Lewis, A. Barry, M.A. Hawkins
    Clinical Oncology.2022; 34(5): e195.     CrossRef
  • Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity
    Shirley Lewis, Laura Dawson, Aisling Barry, Teodor Stanescu, Issa Mohamad, Ali Hosni
    JHEP Reports.2022; 4(8): 100498.     CrossRef
  • The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences
    Yulin Hu, Caining Zhao, Ren Ji, Wenqi Chen, Qi Shen, CL Chiang, Jeff Chan, Lingyu Ma, Hongwei Yang, Tiffany Wong, Susannah Ellsworth, Chung-Mau Lo, Laura A. Dawson, Feng-Ming (Spring) Kong
    Journal of the National Cancer Center.2022; 2(3): 171.     CrossRef
  • Prognosis and Risk Factors of Recurrence in HBV-Related Small Hepatocellular Carcinoma After Stereotactic Body Radiation Therapy
    Yifan Han, Jianxiang Liu, Jiali Pan, Hongyu Chen, Ning Tan, Qian Kang, Yuqing Yang, Xiaoyuan Xu, Wengang Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • High rates of treatment stage migration for early hepatocellular carcinoma and association with adverse outcomes: An Australian multicenter study
    Kee Fong Loo, Richard J Woodman, Damjana Bogatic, Vidyaleha Chandran, Kate Muller, Mohamed Asif Chinnaratha, John Bate, Kirsty Campbell, Matthew Maddison, Sumudu Narayana, Hien Le, David Pryor, Alan Wigg
    JGH Open.2022; 6(9): 599.     CrossRef
  • Stereotactic body radiotherapy versus radiofrequency ablation as initial treatment of small hepatocellular carcinoma
    Hwang Sik Shin, Sae Hwan Lee, Baek Gyu Jun, Hong Soo Kim, Seong Hee Kang, Ji Young Park, Soo In Choi, Gab Jin Cheon, Young Don Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Ki Tae Suk, Dong Joon Kim, In Young Jo, Yong
    European Journal of Gastroenterology & Hepatology.2022; 34(11): 1187.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Clinical and Molecular Hepatology.2022; 28(4): 583.     CrossRef
  • Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    Cancers.2022; 14(20): 5002.     CrossRef
  • Stereotactic body radiation therapy for elderly patients with small hepatocellular carcinoma: a retrospective observational study
    Jeong Yun Jang, Jinhong Jung, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jin-hong Park, Sang Min Yoon
    Journal of Liver Cancer.2022; 22(2): 136.     CrossRef
  • 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2022; 23(12): 1126.     CrossRef
  • Image-Guided Proton Therapy for Elderly Patients with Hepatocellular Carcinoma: High Local Control and Quality of Life Preservation
    Hiromitsu Iwata, Hiroyuki Ogino, Yukiko Hattori, Koichiro Nakajima, Kento Nomura, Kensuke Hayashi, Toshiyuki Toshito, Shigeru Sasaki, Shingo Hashimoto, Jun-etsu Mizoe, Yuta Shibamoto
    Cancers.2021; 13(2): 219.     CrossRef
  • A New Prognostic Model for Radiation-Based Hepatocellular Carcinoma Treatment
    Ting-Shi Su, Shi-Xiong Liang, Li-Qing Li, Qiu-Hua Liu, Xue-Zhang Duan, Jing Sun, Hai Zeng, Jian-Xu Li, Xiao-Fei Zhu, Hong-Qing Zhuang, Ping Liang
    SSRN Electronic Journal .2021;[Epub]     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
    Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2021; 28(6): 951.     CrossRef
  • Radiofrequency ablation versus stereotactic body radiation therapy for small (≤ 3 cm) hepatocellular carcinoma: A retrospective comparison analysis
    Yuri Jeong, Kyung Jin Lee, So Jung Lee, Yong Moon Shin, Min‐Ju Kim, Young‐Suk Lim, Han Chu Lee, Jinhong Jung, Jin‐hong Park, Jong Hoon Kim, So Yeon Kim, Sang Min Yoon
    Journal of Gastroenterology and Hepatology.2021; 36(7): 1962.     CrossRef
  • Updates on the Diagnosis and Management of Hepatocellular Carcinoma
    Muhammad Kamran, Aimun Raees, Wasim Jafri
    Euroasian Journal of Hepato-Gastroenterology.2021; 11(1): 32.     CrossRef
  • Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study
    Ting-Shi Su, Qiu-Hua Liu, Xiao-Fei Zhu, Ping Liang, Shi-Xiong Liang, Lin Lai, Ying Zhou, Yong Huang, Tao Cheng, Le-Qun Li
    Radiation Oncology.2021;[Epub]     CrossRef
  • Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
  • Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe
    Sung Uk Lee, Sang Min Yoon, Jason Chia-Hsien Cheng, Tae Hyun Kim, Bo Hyun Kim, Jin-hong Park, Jinhong Jung, Chiao-Ling Tsai, Yun Chiang, Joong-Won Park
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Hepatology International.2021; 15(5): 1083.     CrossRef
  • Stereotactic body radiotherapy vs radiofrequency ablation for the treatment of hepatocellular carcinoma: a meta-analysis
    Antonio Facciorusso, Andrea Chierici, Ivan Cincione, Rodolfo Sacco, Daryl Ramai, Babu P Mohan, Saurabh Chandan, Andrew Ofosu, Christian Cotsoglou
    Expert Review of Anticancer Therapy.2021; 21(6): 681.     CrossRef
  • Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2021; 13(23): 5892.     CrossRef
  • In reply to Huo et al.: Treating small hepatocellular carcinoma: Stereotactic body radiation therapy versus radiofrequency ablation
    S Park, J Jung, B Cho, SY Kim, S‐C Yun, Y‐S Lim, HC Lee, J Park, J‐h Park, JH Kim, SM Yoon
    Journal of Gastroenterology and Hepatology.2020; 35(12): 2293.     CrossRef
  • 11,472 View
  • 227 Download
  • 62 Web of Science
  • Crossref

Editorial

Hepatic neoplasm

Citations

Citations to this article as recorded by  Crossref logo
  • Micro-Nano Convergence-Driven Radiotheranostic Revolution in Hepatocellular Carcinoma
    Yisheng Peng, Hui Liu, Mengmeng Miao, Xu Cheng, Shangqing Chen, Kaifei Yan, Jing Mu, Hongwei Cheng, Gang Liu
    ACS Applied Materials & Interfaces.2025; 17(20): 29047.     CrossRef
  • 10,155 View
  • 157 Download
  • 1 Web of Science
  • Crossref

Review

Hepatic neoplasm

Strategic application of radiotherapy for hepatocellular carcinoma
Seo Hee Choi, Jinsil Seong
Clin Mol Hepatol 2018;24(2):114-134.
Published online February 14, 2018
DOI: https://doi.org/10.3350/cmh.2017.0073
With increasing clinical use, radiotherapy (RT) has been considered reliable and effective method for hepatocellular carcinoma (HCC) treatment, depending on extent of disease and patient characteristics. RT for HCC can improve therapeutic outcomes through excellent local control, downstaging, conversion from unresectable to resectable status, and treatments of unresectable HCCs with vessel invasion or multiple intrahepatic metastases. In addition, further development of modern RT technologies, including image-guided radiotherapy (IGRT), intensity-modulated radiotherapy (IMRT), and stereotactic body radiotherapy, has expanded the indication of RT. An essential feature of IGRT is that it allows image guidance therapy through in-room images obtained during radiation delivery. Compared with 3D-conformal RT, distinctions of IMRT are inverse treatment planning process and use of a large number of treatment fields or subfields, which provide high precision and exquisitely conformal dose distribution. These modern RT techniques allow more precise treatment by reducing inter- and intra-fractional errors resulting from daily changes and irradiated dose at surrounding normal tissues. More recently, particle therapy has been actively investigated to improve effectiveness of RT. This review discusses modern RT strategies for HCC, as well as optimal selection of RT in multimodal approach for HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Effect of Narrow-Margin Hepatectomy Combined with Intraoperative Radiotherapy on Long-Term Prognosis of Patients with Centrally Located Hepatocellular Carcinoma: A Propensity Score Matching Analysis
    Changcheng Tao, Liguo Liu, Nan Hu, Hongwei Wang, Kai Zhang, Yue Liu, Fan Wu, Liming Wang, Weiqi Rong, Jianxiong Wu
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 261.     CrossRef
  • Microenvironment-triggered copper peroxide and tannic acid cooperatively iron-coordinated nanocomposites for oxidative stress-enhanced radiotherapy of hepatocellular carcinoma
    Zipeng Lei, Jiaqi Liao, Huiqin Yao, Xiaoting Zhou, Chun Yang, Qihui Wang, Hailong Jin, Xiao He, Qing Zhang, Yan Zu
    Nano Today.2025; 63: 102771.     CrossRef
  • Micro-Nano Convergence-Driven Radiotheranostic Revolution in Hepatocellular Carcinoma
    Yisheng Peng, Hui Liu, Mengmeng Miao, Xu Cheng, Shangqing Chen, Kaifei Yan, Jing Mu, Hongwei Cheng, Gang Liu
    ACS Applied Materials & Interfaces.2025; 17(20): 29047.     CrossRef
  • Report from the 26th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Hepatocellular and Biliary Tract Cancer, Saskatoon, Saskatchewan, 17–18 October 2024
    Deepti Ravi, Shahid Ahmed, Blaire Anderson, Brady Anderson, Bryan Brunet, Haji Chalchal, Arun Elangovan, Georgia Geller, Vallerie Gordon, Branawan Gowrishankar, Edward Hardy, Mussawar Iqbal, Duc Le, Richard Lee-Ying, Shazia Mahmood, Karen Mulder, Maged Na
    Current Oncology.2025; 32(7): 398.     CrossRef
  • Effects of three-dimensional conformal radiotherapy and image-guided radiotherapy on patients with liver cancer
    F. Xu, P. Xu
    International Journal of Radiation Research.2025; 23(3): 563.     CrossRef
  • The Rac1-USP11 feedback amplification loop: a radiation-activated engine driving radioresistance in hepatocellular carcinoma
    Kaixiao Zhou, Yabo Jiang, Jiahao Guo, Haobo Zhang, Yuhao Hu, Xuanyu Meng, Yecheng Li, Shaohua Wei, Jian Wang, Xubiao Wei, Shuqun Cheng, Jianping Cao, Yang Jiao
    British Journal of Cancer.2025;[Epub]     CrossRef
  • A review of deep learning approaches for multimodal image segmentation of liver cancer
    Chaopeng Wu, Qiyao Chen, Haoyu Wang, Yu Guan, Zhangyang Mian, Cong Huang, Changli Ruan, Qibin Song, Hao Jiang, Jinghui Pan, Xiangpan Li
    Journal of Applied Clinical Medical Physics.2024;[Epub]     CrossRef
  • Dual-doped metalloporphyrin MOFs-based nanoagent increases low-dose radiotherapy efficacy by apoptosis-ferroptosis for hepatocellular carcinoma
    Xinxin Wang, Jianmin Zhou, Yanlin Zhu, Can Yu, Di Sun, Yuanfei Yao, Lili Feng, Piaoping Yang, Yang Zhou
    Chemical Engineering Journal.2024; 501: 157645.     CrossRef
  • Autophagy-based therapy for hepatocellular carcinoma: from standard treatments to combination therapy, oncolytic virotherapy, and targeted nanomedicines
    Fereshteh Rahdan, Fatemeh Abedi, Hassan Dianat-Moghadam, Maryam Zamani Sani, Mohammad Taghizadeh, Effat Alizadeh
    Clinical and Experimental Medicine.2024;[Epub]     CrossRef
  • Prognostic value of lymphocyte subset levels in hepatocellular carcinoma following conventionally fractionated vs. stereotactic body radiotherapy
    Si-Tong Wang, Yi-Xing Chen, Yu-Nan Gao, Ping Yang, Qian-Qian Zhao, Zhao-Chong Zeng, Yuan Zhuang
    Hepatoma Research.2024;[Epub]     CrossRef
  • Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial–Mesenchymal Transition and Metastasis
    Yueh-Shan Weng, I-Tsang Chiang, Jai-Jen Tsai, Yu-Chang Liu, Fei-Ting Hsu
    International Journal of Radiation Oncology*Biology*Physics.2023; 115(3): 719.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Journal of Liver Cancer.2023; 23(1): 1.     CrossRef
  • Radionuclide‐Labeled Microspheres for Radio‐Immunotherapy of Hepatocellular Carcinoma
    Sai Yang, Chongjing Mu, Teng Liu, Pei Pei, Wenhao Shen, Yanxiang Zhang, Guanglin Wang, Lei Chen, Kai Yang
    Advanced Healthcare Materials.2023;[Epub]     CrossRef
  • Advances in radiotherapy and immunity in hepatocellular carcinoma
    Yuhan Yang, Liting Xiong, Mengyuan Li, Ping Jiang, Junjie Wang, Chunxiao Li
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • Attenuated Salmonella carrying siRNA-PD-L1 and radiation combinatorial therapy induces tumor regression on HCC through T cell-mediated immuno-enhancement
    Huijie Jia, Pengkun Wei, Shijie Zhou, Yuanyuan Hu, Chunjing Zhang, Lirui Liang, Bingqing Li, Zerui Gan, Yuanling Xia, Hanyu Jiang, Mingguang Shao, Sheng Guo, Zishan Yang, Jiateng Zhong, Feng Ren, Huiyong Zhang, Yongxi Zhang, Tiesuo Zhao
    Cell Death Discovery.2023;[Epub]     CrossRef
  • Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma
    Hwa Kyung Byun, Changhwan Kim, Jinsil Seong
    Clinical and Molecular Hepatology.2023; 29(4): 945.     CrossRef
  • Impact of Intrahepatic External Beam Radiotherapy in Advanced Hepatocellular Carcinoma Patients Treated with Tyrosine Kinase Inhibitors
    Myung Ji Goh, Hee Chul Park, Jeong Il Yu, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Dong Hyun Sinn, Moon Seok Choi
    Liver Cancer.2023; 12(5): 467.     CrossRef
  • Large hepatocellular carcinoma treated with sequential SBRT and immunotherapy with anti-VEGF (Vascular Endothelial Growth Factor) therapy
    Bardia Bidarmaghz, Marwan Idrees, Yoo Young Lee, Peter Hodgkinson
    BMJ Case Reports.2023; 16(12): e256931.     CrossRef
  • MiR-122 radiosensitize hepatocellular carcinoma cells by suppressing cyclin G1
    Gang Xu, Shanshan Bu, Xiushen Wang, Hong Ge
    International Journal of Radiation Biology.2022; 98(1): 11.     CrossRef
  • Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
    Jina Kim, Hwa Kyung Byun, Tae Hyung Kim, Sun Il Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Jinsil Seong
    Cancers.2022; 14(10): 2396.     CrossRef
  • Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study
    Jian-Xu Li, Wen-Xiang Deng, Shi-Ting Huang, Xiao-Feng Lin, Mei-Ying Long, Jie Zhang, Ting-Shi Su, Li-Qing Li, Ya-Dan Pang, Chun-Feng Liang, Hong-Mei Zhou, Hai-Yan Lu, Shi-Xiong Liang, Bang-De Xiang
    Radiation Oncology.2022;[Epub]     CrossRef
  • The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy
    Ying Xu, Yi Yang, Lu Li, Feng Ye, Xinming Zhao
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Clinical and Molecular Hepatology.2022; 28(4): 583.     CrossRef
  • 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2022; 23(12): 1126.     CrossRef
  • External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Han Li, Zhenying Wu, Jiali Chen, Ke Su, Lu Guo, Ke Xu, Tao Gu, Yi Jiang, Pan Wang, Hao Zeng, Hao Chi, Kun He, Yunwei Han
    Clinical and Experimental Medicine.2022; 23(5): 1537.     CrossRef
  • Dose-Response Relationship in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study
    Nalee Kim, Jason Cheng, Wen-Yen Huang, Tomoki Kimura, Zhao Chong Zeng, Victor H.F. Lee, Chul Seung Kay, Jinsil Seong
    International Journal of Radiation Oncology*Biology*Physics.2021; 109(2): 464.     CrossRef
  • Optimal Timing of Radiotherapy after Incomplete Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
    Hwa Kyung Byun, Nalee Kim, Jinsil Seong
    Yonsei Medical Journal.2021; 62(5): 409.     CrossRef
  • PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair
    Yinghai Xie, Changwei Liu, Yinci Zhang, Amin Li, Chong Sun, Rui Li, Yingru Xing, Minghong Shi, Qi Wang, Yi-Hsien Hsieh
    PLOS ONE.2021; 16(10): e0258817.     CrossRef
  • Lupeol-Loaded Nanoparticles Enhance the Radiosensitivity of Hepatocellular Carcinoma by Inhibiting the Hyperactivation in Raf/Mitogen-Activated Protein Kinase and Phospatidylinositol-3 Kinase/mTOR Pathways
    Yinghai Xie, Changwei Liu, Shuping Zhou, Qi Wang, Xiaolong Tang
    Journal of Biomedical Nanotechnology.2021; 17(11): 2247.     CrossRef
  • CT‐guided liver beacon transponder implantation
    Yufeng Zhang, Xia He, Wenjie Guo, Li Sun, Chang Guo, Yong Feng
    Precision Medical Sciences.2021; 10(1): 42.     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases
    Chang Liu, Yu‐Li Wang, Yong‐Yu Yang, Ning‐Ping Zhang, Chen Niu, Xi‐Zhong Shen, Jian Wu
    The FASEB Journal.2021;[Epub]     CrossRef
  • MR-Guided Radiotherapy for Liver Malignancies
    Luca Boldrini, Stefanie Corradini, Cihan Gani, Lauren Henke, Ali Hosni, Angela Romano, Laura Dawson
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • ATF2-Induced Overexpression of lncRNA LINC00882, as a Novel Therapeutic Target, Accelerates Hepatocellular Carcinoma Progression via Sponging miR-214-3p to Upregulate CENPM
    Hua Ren, Zhi-cheng Wei, Yan-xia Sun, Chun-yan Qiu, Wen-jue Zhang, Wei Zhang, Tao Liu, Xu Che
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • KIF2C promotes the proliferation of hepatocellular carcinoma cells in vitro and in vivo
    Zhenya Gao, Huanxia Jia, Fang Yu, Hongfang Guo, Baoyu Li
    Experimental and Therapeutic Medicine.2021;[Epub]     CrossRef
  • Silencing the Expression of Cyclin G1 Enhances the Radiosensitivity of Hepatocellular Carcinoma In Vitro and In Vivo by Inducing Apoptosis
    Gang Xu, Shanshan Bu, Xiushen Wang, Hong Ge
    Radiation Research.2021;[Epub]     CrossRef
  • Delayed response to proton beam treatment of hepatocellular carcinoma
    Chee-Wai Cheng, Mitchell Machtay, Jennifer Dorth, Olga Sergeeva, Hangsheng Xia, chawan manaspon, Hanping wu, Renuka Iyer, Sandra Sexton, Wei Xin, Agata A Exner, Zhenghong Lee
    BJR|case reports.2020; 6(1): 20180125.     CrossRef
  • Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma
    Nalee Kim, Jason Cheng, Inkyung Jung, Ja Der Liang, Yu Lueng Shih, Wen-Yen Huang, Tomoki Kimura, Victor H.F. Lee, Zhao Chong Zeng, Ren Zhenggan, Chul Seung Kay, Seok Jae Heo, Jong Yoon Won, Jinsil Seong
    Journal of Hepatology.2020; 73(1): 121.     CrossRef
  • Circular RNA TUBD1 Acts as the miR-146a-5p Sponge to Affect the Viability and Pro-Inflammatory Cytokine Production of LX-2 Cells through the TLR4 Pathway
    Hao Niu, Li Zhang, Yu-Han Chen, Bao-Ying Yuan, Zhi-Feng Wu, Jason Chia-Hsien Cheng, Qin Lin, Zhao-Chong Zeng
    Radiation Research.2020; 193(4): 383.     CrossRef
  • Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation
    Byung-Yoon Yun, Hye Won Lee, In Kyung Min, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2020; 12(9): 2527.     CrossRef
  • Huge Hepatocellular Carcinoma Exhibiting a Complete Response after Stereotactic Body Radiation Therapy
    Kyung In Shin, Byoung Kuk Jang, Jin Hee Kim, Jae Seok Hwang
    Journal of Liver Cancer.2020; 20(2): 167.     CrossRef
  • Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry
    Young Eun Chon, Han Ah Lee, Jun Sik Yoon, Jun Yong Park, Bo Hyun Kim, In Joon Lee, Suk Kyun Hong, Dong Hyeon Lee, Hyun-Joo Kong, Eunyang Kim, Young-Joo Won, Jeong-Hoon Lee
    Journal of Liver Cancer.2020; 20(2): 135.     CrossRef
  • External beam radiation therapy in a centenarian with primary liver cancer
    Zhen Meng, Feifei Gao, Chang Liu, Shengcai Huang, Kai Hu, Rensheng Wang
    Medicine.2020; 99(47): e22473.     CrossRef
  • Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma
    Hwa Kyung Byun, Nalee Kim, Sangjoon Park, Jinsil Seong
    Strahlentherapie und Onkologie.2019; 195(11): 1007.     CrossRef
  • Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation
    Chang Gon Kim, Hyun Woong Lee, Hye Jin Choi, Jung Il Lee, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han, Han Sang Kim, Kyung Hwan Kim, Seong Jin Choi, Yongun Kim, Kwan Sik Lee, Gyoung Min Kim, Man Deuk Kim, Jong Yoo
    Cancer Medicine.2019; 8(11): 5023.     CrossRef
  • Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C
    Yeon Joo Kim, Jinhong Jung, Ji Hyeon Joo, So Yeon Kim, Jin Hyoung Kim, Young-Suk Lim, Han Chu Lee, Jong Hoon Kim, Sang Min Yoon
    Radiotherapy and Oncology.2019; 141: 95.     CrossRef
  • Radiation-induced Myositis after Proton Beam Therapy to Huge Hepatocellular Carcinoma
    Jihye Kim, Gyu Sang Yoo, Dong Hyun Sinn, Hee Chul Park, Kwang Cheol Koh
    Journal of Liver Cancer.2019; 19(2): 136.     CrossRef
  • Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study
    Beom Kyung Kim, Do Young Kim, Kwang-Hyub Han, Jinsil Seong, Jung Weon Lee
    PLOS ONE.2019; 14(10): e0223678.     CrossRef
  • Knockdown of interferon‑stimulated gene 15 affects the sensitivity of hepatocellular carcinoma cells to norcantharidin
    Baoxiang Chen, Shuqiang Jin, Bin Bai, Zhi Li, Caifang Ni, Yansen Liu
    Experimental and Therapeutic Medicine.2019;[Epub]     CrossRef
  • Novel thioureido-benzenesulfonamide derivatives with enaminone linker as potent anticancer, radiosensitizers and VEGFR2 inhibitors
    Mostafa M. Ghorab, Fatma A. Ragab, Helmy I. Heiba, Marwa G. El-Gazzar, Mostafa G.M. El-Gazzar
    Bioorganic & Medicinal Chemistry Letters.2018; 28(9): 1464.     CrossRef
  • Proton beam therapy in apneic oxygenation treatment of an unresectable hepatocellular carcinoma: A case report and review of literature
    Yi-Lan Lin
    World Journal of Hepatology.2018; 10(10): 772.     CrossRef
  • 18,460 View
  • 406 Download
  • 46 Web of Science
  • Crossref

Case Report

Hepatic neoplasm

Primary squamous cell carcinoma of the liver: a case report
Tae Kyung Yoo, Byung Ik Kim, Eun Na Han, Dong Hyung Kim, Jung Hee Yoo, Seung Jae Lee, Yong Kyun Cho, Hong Joo Kim
Clin Mol Hepatol 2016;22(1):177-182.
Published online March 28, 2016
DOI: https://doi.org/10.3350/cmh.2016.22.1.177
Primary squamous cell carcinoma (SCC) of the liver is very rare, and few cases have been reported in Korea. Primary SCC of the liver is known to be associated with hepatic cysts and intrahepatic stones. A 71-year-old male was admitted to our hospital, and a abdominal computed tomography scan revealed a 10 × 6 cm mass in the liver. Analysis of a biopsy sample suggested SCC, and so our team performed a thorough workup to find the primary lesion, which was revealed hepatoma as a pure primary SCC of the liver with multiple distant metastases. The patient was treated with one cycle of radiotherapy, transferred to another hospital for hospice care, and then died 1 month after discharge.

Citations

Citations to this article as recorded by  Crossref logo
  • Clinical Outcomes of Hepatic Squamous Cell Carcinoma With Fibroblast Growth Factor Receptor 2 (FGFR2) Mutation: A Case Report
    Ryogo Minami, Masamichi Kimura, Koji Nishikawa, Jun Imamura, Kiminori Kimura
    Cureus.2025;[Epub]     CrossRef
  • Immunotherapy for primary squamous cell carcinoma of the liver: A case report
    Jian Jiang, Guomin Dong, Suoni Li, Jiequn Ma, Jie Bai, Jinzi Hui, Hongbian Gao, Zheng Zhao
    Oncology Letters.2025; 29(6): 1.     CrossRef
  • Primary hepatic squamous cell carcinoma with pseudoachalasia treated with TACE: Case report and literature review
    Yang He, Hang Du, An Tianzhi
    Radiology Case Reports.2025; 20(10): 4906.     CrossRef
  • Primary Hepatic Squamous Cell Carcinoma: A Case Report
    Manal Lyagoubi, Chourouq Mehdaoui, Anass Haloui, Nassira Karish, Zahi Ismaili, Amal Bennani
    Cureus.2024;[Epub]     CrossRef
  • A case report of primary intrahepatic adeno squamous cell cholangiocarcinoma
    Fionn Woulfe, Michael Devine, Brian Hayes, Rory Crotty, Adrian O'Sullivan
    International Journal of Surgery Case Reports.2024; 124: 110366.     CrossRef
  • Diagnostic value of imaging modalities in primary squamous cell carcinoma of the liver
    Yuxuan Song, Jiahong Shi, Xiujuan Zhang, Meng Qiao, Zhixia Sun, Siyu Tian
    Journal of Clinical Ultrasound.2023; 51(5): 887.     CrossRef
  • Immunotherapy as adjuvant therapy for a patient with adenosquamous carcinoma of the intrahepatic bile duct: A case report and literature review
    Jun Feng, Aimaiti Yasen, Tianxing Dai, Runbin Liang, Zhihong Liao, Ping He, Zhihong Lin, Guoying Wang
    Liver Research.2023; 7(2): 156.     CrossRef
  • Unusual Case of Primary Hepatic Squamous Carcinoma on 18F-FDG PET/CT
    Wei Li, Zhidong Liu, Rusen Zhang
    Clinical Nuclear Medicine.2023; 48(12): e596.     CrossRef
  • Primary hepatic squamous cell carcinoma: case report and systematic review of the literature
    Lin Zhao, Yan Zhou, Jianmin Ding, Zhengyi Qin, Hongyu Zhou, Xiang Jing
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Primary squamous cell carcinoma of the liver: A case report
    Li-Min Kang, Di-Ping Yu, Yong Zheng, Ya-Hao Zhou
    World Journal of Clinical Cases.2022; 10(19): 6744.     CrossRef
  • Primary squamous cell carcinoma of liver. First case report from Pakistan and South Asia
    Muhammad Atiq, Ahmed Siddique Ammar, Rabia Mahmood Ali, Siraj Haider, Imran Ahmed, Faisal Saud Dar
    International Journal of Surgery Case Reports.2022; 99: 107655.     CrossRef
  • Primary Squamous Cell Carcinoma of the Liver with Good Response to Carboplatin and 5-Flurouracil: A Case Report
    Hsu-Lin Lee, Chun-Kai Fu, Liang-Yu Chien, Li-Mien Chen
    Medicina.2022; 58(12): 1864.     CrossRef
  • Primary squamous cell carcinoma of the liver: a case report
    Yu Sun, Guangyu Jin
    Journal of International Medical Research.2021;[Epub]     CrossRef
  • Primary intrahepatic squamous cell carcinoma in a sika deer
    Kazuya MATSUDA, Junji YAMADA, Shun KOGAME, Ryo MURATA, Yuto SANO
    Journal of Veterinary Medical Science.2020; 82(2): 135.     CrossRef
  • Primary squamous cell carcinoma of the liver: an unexpected pathological finding
    Fabio Tuminello, Davide Castiglione, Giuseppe Broggi, Giada Maria Vecchio, Antonio Basile, Stefano Puleo, Antonio Pesce
    Egyptian Liver Journal.2020;[Epub]     CrossRef
  • Primary hepatic squamous cell carcinoma with abdominal incision metastasis after hepatectomy
    Jia-Xi Mao, Fei Teng, Hang Yuan, Cong Liu, Hong Fu, Ke-Yan Sun, Guo-Shan Ding, Wen-Yuan Guo
    Hepatobiliary & Pancreatic Diseases International.2019; 18(2): 194.     CrossRef
  • 15,129 View
  • 141 Download
  • 17 Web of Science
  • Crossref

Original Article

Hepatic neoplasm

Influence of P53 on the radiotherapy response of hepatocellular carcinoma
Ana R. Gomes, Ana M. Abrantes, Ana F. Brito, Mafalda Laranjo, João E. Casalta-Lopes, Ana C. Gonçalves, Ana B. Sarmento-Ribeiro, Maria F. Botelho, José G. Tralhão
Clin Mol Hepatol 2015;21(3):257-267.
Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.257
Background/Aims

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and it has a poor prognosis and few therapeutic options. Radiotherapy is one of the most effective forms of cancer treatment, and P53 protein is one of the key molecules determining how a cell responds to radiotherapy. The aim of this study was to determine the therapeutic efficacy of iodine-131 in three human HCC cell lines.

Methods

Western blotting was used to measure P53 expression. The effects of radiotherapy with iodine-131 were assessed by using the clonogenic assay to evaluate cell survival. Flow cytometry was carried out to examine the effects of iodine-131 on cell death, oxidative stress, reduced intracellular glutathione expression, the mitochondrial membrane potential, and the cell cycle.

Results

The P53 protein was not expressed in Hep3B2.1-7 cells, was expressed at normal levels in HepG2 cells, and was overexpressed in HuH7 cells. P53 expression in the HuH7 and HepG2 cell lines increased after internal and external irradiation with iodine-131. Irradiation induced a decrease in cell survival and led to a decrease in cell viability in all of the cell lines studied, accompanied by cell death via late apoptosis/necrosis and necrosis. Irradiation with 131-iodine induced mostly cell-cycle arrest in the G0/G1 phase.

Conclusions

These results suggest that P53 plays a key role in the radiotherapy response of HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Site-specific delivery of pectin-stabilized gold nanoparticles for liver: An in vivo evaluation with Doxorubicin
    Mayank Kumar Singh, Sophia Mckenzie Schulte, Rohith Kumar, Shilpa Kumar, Swati Singh, Abhay Singh Chauhan
    Journal of Drug Delivery Science and Technology.2025; 111: 107118.     CrossRef
  • The potential of gold nanoparticles in prostate-specific membrane antigen-targeted radioligand therapy for future treatment of metastatic castration-resistant prostate cancer
    Sumandi Juliyanto, Rien Ritawidya, Ahsanal Fikri, Amal Rezka Putra, Herlan Setiawan, Maskur, Muammar Fawwaz, Yoki Yulizar
    Journal of Radioanalytical and Nuclear Chemistry.2025; 334(11): 7573.     CrossRef
  • Overcoming radioresistance of breast cancer cells with MAP4K4 inhibitors
    Yun-Suk Kwon, Min-Gu Lee, Nam-Yi Kim, Gi Suk Nam, Kyung-Soo Nam, Hyunsoo Jang, Soyoung Kim
    Scientific Reports.2024;[Epub]     CrossRef
  • Effect of proton-beam irradiation on cell survival of MCF-7 and its chemo-resistant subgroups
    Sushma Maharjan, Min-Gu Lee, Kyung-Soo Nam, Kyu-Shik Lee
    Journal of the Korean Physical Society.2024; 85(3): 271.     CrossRef
  • Advances in radiotherapy and immunity in hepatocellular carcinoma
    Yuhan Yang, Liting Xiong, Mengyuan Li, Ping Jiang, Junjie Wang, Chunxiao Li
    Journal of Translational Medicine.2023;[Epub]     CrossRef
  • Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity
    Shirley Lewis, Laura Dawson, Aisling Barry, Teodor Stanescu, Issa Mohamad, Ali Hosni
    JHEP Reports.2022; 4(8): 100498.     CrossRef
  • Radiation Response of Human Leukemia/Lymphoma Cells was Improved by 7-Geranyloxycoumarin
    Ramin Bagheri, Fatemeh B. Rassouli, Hamid Gholamhosseinian, Keyhan Ebrahimi, Shakiba Mahdavi, Sajad Goudarzi, Mehrdad Iranshahi, Houshang Rafatpanah, Mohammad Reza Keramati
    Dose-Response.2022;[Epub]     CrossRef
  • Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches
    Zahra Farzaneh, Massoud Vosough, Tarun Agarwal, Maryam Farzaneh
    Cancer Cell International.2021;[Epub]     CrossRef
  • In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma
    Fredrik Kullenberg, Oliver Degerstedt, Carlemi Calitz, Nataša Pavlović, David Balgoma, Johan Gråsjö, Erik Sjögren, Mikael Hedeland, Femke Heindryckx, Hans Lennernäs
    Cells.2021; 10(7): 1717.     CrossRef
  • Crosstalk between ER-stress and apoptosis in irradiated HepG2 cells with gemcitabine: implication of PI3K/AKT and IκB/NF-κB signaling pathways
    Enas Mahmoud Moustafa, Laila Ahmed Rashed, Mohammed M. El-Sebaie, Noura Magdy Thabet, Mohamed Khairy Abdel-Rafei
    Journal of Radiation Research and Applied Sciences.2020; 13(1): 144.     CrossRef
  • Metals and low dose IR: Molecular effects of combined exposures using HepG2 cells as a biological model
    A. Campos, R. Pereira, A. Vaz, T. Caetano, M. Malta, J. Oliveira, F.P. Carvalho, S. Mendo, J. Lourenço
    Journal of Hazardous Materials.2020; 396: 122634.     CrossRef
  • Proton Beam Induces P53-mediated Cell Cycle Arrest in HepG2 Hepatocellular Carcinoma Cells
    So-Young Chun, Kyung-Soo Nam, Kyu-Shik Lee
    Biotechnology and Bioprocess Engineering.2020; 25(2): 141.     CrossRef
  • β-radiating radionuclides in cancer treatment, novel insight into promising approach
    Samieh Asadian, Hamed Mirzaei, Bagher Aziz Kalantari, Mohamad Reza Davarpanah, Morteza Mohamadi, Anastasia Shpichka, Leila Nasehi, Hamidreza Aboulkheyr Es, Peter Timashev, Mustapha Najimi, Nematollah Gheibi, Moustapha Hassan, Massoud Vosough
    Pharmacological Research.2020; 160: 105070.     CrossRef
  • RETRACTED: ZFP36 Binds With PRC1 to Inhibit Tumor Growth and Increase 5-Fu Chemosensitivity of Hepatocellular Carcinoma
    Weiqian Chen, Minjiang Chen, Zhongwei Zhao, Qiaoyou Weng, Jingjing Song, Shiji Fang, Xulu Wu, Hailin Wang, Dengke Zhang, Weibin Yang, Zufei Wang, Min Xu, Jiansong Ji
    Frontiers in Molecular Biosciences.2020;[Epub]     CrossRef
  • Iodine‑131 metabolic radiotherapy leads to cell death and genomic alterations through NIS overexpression on cholangiocarcinoma
    Ana Brito, Ana Abrantes, Ricardo Teixo, Ana Pires, Ana Ribeiro, Rafael Ferreira, Alexandra Fernandes, Tiago Puga, Mafalda Laranjo, Francisco Caramelo, Ilka Boin, Douglas Jefferson, Ana Gon�alves, Ricardo Martins, Joana Rodrigues, Ilda Ribe
    International Journal of Oncology.2020;[Epub]     CrossRef
  • HNF4α regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer
    Qing Xu, Yuanyuan Li, Xia Gao, Kai Kang, Jason G. Williams, Lingfeng Tong, Juan Liu, Ming Ji, Leesa J. Deterding, Xuemei Tong, Jason W. Locasale, Leping Li, Igor Shats, Xiaoling Li
    Nature Communications.2020;[Epub]     CrossRef
  • The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation
    Melanie Dzulko, Miriam Pons, Andreas Henke, Günter Schneider, Oliver H. Krämer
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2020; 1874(2): 188453.     CrossRef
  • Lipoproteins-Nanocarriers as a Promising Approach for Targeting Liver Cancer: Present Status and Application Prospects
    Saleh A. Alanazi, Fars Alanazi, Nazrul Haq, Faiyaz Shakeel, Mohamed M. Badran, Gamaleldin I. Harisa
    Current Drug Delivery.2020; 17(10): 826.     CrossRef
  • PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway
    Xuemei Yang, Qian Zhang, Xiaofeng Yang, Minyi Zhao, Ting Yang, Anmei Yao, Xiaofei Tian
    Biochemical and Biophysical Research Communications.2019; 511(4): 719.     CrossRef
  • Growth arrest-specific gene 2 suppresses hepatocarcinogenesis by intervention of cell cycle and p53-dependent apoptosis
    Ran-Xu Zhu, Alfred Sze Lok Cheng, Henry Lik Yuen Chan, Dong-Ye Yang, Wai-Kay Seto
    World Journal of Gastroenterology.2019; 25(32): 4715.     CrossRef
  • Growth arrest-specific gene 2 suppresses hepatocarcinogenesis by intervention of cell cycle and p53-dependent apoptosis
    Ran-Xu Zhu, Alfred Sze Lok Cheng, Henry Lik Yuen Chan, Dong-Ye Yang, Wai-Kay Seto
    World Journal of Gastroenterology.2019; 25(32): 4673.     CrossRef
  • Adenosine deaminase acting on RNA-1 (ADAR1) inhibits hepatitis B virus (HBV) replication by enhancing microRNA-122 processing
    Guangyan Liu, Xiancai Ma, Zhe Wang, Kousho Wakae, Yaochang Yuan, Zhangping He, Hironori Yoshiyama, Hisashi Iizasa, Hui Zhang, Mami Matsuda, Ryuichi Sugiyama, Zhiyu Yuan, Masamichi Muramatsu, Linghua Li
    Journal of Biological Chemistry.2019; 294(38): 14043.     CrossRef
  • Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review
    Saleh Daher, Muhammad Massarwa, Ariel A. Benson, Tawfik Khoury
    Journal of Clinical and Translational Hepatology.2018; 6(1): 1.     CrossRef
  • MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?
    Samy Azer
    Journal of Clinical Medicine.2018; 7(4): 64.     CrossRef
  • Differential Radiation Sensitivity in p53 Wild-Type and p53-Deficient Tumor Cells Associated with Senescence but not Apoptosis or (Nonprotective) Autophagy
    Jingwen Xu, Nipa H. Patel, Tareq Saleh, Emmanuel K. Cudjoe, Moureq Alotaibi, Yingliang Wu, Santiago Lima, Adam M. Hawkridge, David A. Gewirtz
    Radiation Research.2018; 190(5): 538.     CrossRef
  • CMA down-regulates p53 expression through degradation of HMGB1 protein to inhibit irradiation-triggered apoptosis in hepatocellular carcinoma
    Jing-Hua Wu, Jia-Pei Guo, Jun Shi, Hui Wang, Lei-Lei Li, Bin Guo, Dian-Xing Liu, Qing Cao, Zhi-Yong Yuan
    World Journal of Gastroenterology.2017; 23(13): 2308.     CrossRef
  • Oxidative Stress, DNA, Cell Cycle/Cell Cycle Associated Proteins and Multidrug Resistance Proteins: Targets of Human Amniotic Membrane in Hepatocellular Carcinoma
    A. C. Mamede, S. Guerra, M. Laranjo, K. Santos, M. J. Carvalho, T. Carvalheiro, P. Moura, A. Paiva, A. M. Abrantes, C. J. Maia, M. F. Botelho
    Pathology & Oncology Research.2016; 22(4): 689.     CrossRef
  • High dose and compartmental target volume may improve patient outcome after radiotherapy for pelvic bone metastases from hepatocellular carcinoma
    Taehyung Kim, Hye Jung Cha, Jun Won Kim, Jinsil Seong, Ik Jae Lee
    Oncotarget.2016; 7(33): 53921.     CrossRef
  • Selective cytotoxicity and cell death induced by human amniotic membrane in hepatocellular carcinoma
    A. C. Mamede, S. Guerra, M. Laranjo, M. J. Carvalho, R. C. Oliveira, A. C. Gonçalves, R. Alves, L. Prado Castro, A. B. Sarmento-Ribeiro, P. Moura, A. M. Abrantes, C. J. Maia, M. F. Botelho
    Medical Oncology.2015;[Epub]     CrossRef
  • 14,857 View
  • 127 Download
  • 33 Web of Science
  • Crossref

Editorial

Hepatic neoplasm

P53 expression in hepatocellular carcinoma: influence on the radiotherapeutic response of the hepatocellular carcinoma
Yu Rim Lee, Soo Young Park
Clin Mol Hepatol 2015;21(3):230-231.
Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.230

Citations

Citations to this article as recorded by  Crossref logo
  • Red rice bran polyphenols suppress invasive properties of HepG2 cells, possibly through Wnt/β-catenin-mediated EMT reversal
    Nattawan Thaolipo, Worawat Surarit, Pintusorn Hansakul
    F1000Research.2025; 14: 407.     CrossRef
  • An Ethanolic Extract of Sulfur Polypore Mushroom Laetiporus sulphureus (Agaricomycetes) Mycelium Inhibits Cell Cycle Progression, Survival, and Migration in Human Hepatocarcinoma Cell Lines
    Martina De Mattheis, Alberto Massimi, Lara Lizzi, Marco Leonardi, Mirco Iotti, Mara Massimi
    International Journal of Medicinal Mushrooms.2025; 27(12): 67.     CrossRef
  • Novel pyrano[2,3-c]pyrazolopyrimidines as promising anticancer agents: Design, synthesis, and cell cycle arrest of HepG2 cells at S phase
    David S. A. Haneen, Mohamed H. Hekal, Wael S. I. Abou-Elmagd, Wael M. El-Sayed
    Synthetic Communications.2024; 54(8): 655.     CrossRef
  • Ribonucleotide reductase subunit switching in hepatoblastoma drug response and relapse
    Anthony Brown, Qingfei Pan, Li Fan, Emilie Indersie, Cheng Tian, Nikolai Timchenko, Liyuan Li, Baranda S. Hansen, Haiyan Tan, Meifen Lu, Junmin Peng, Shondra M. Pruett-Miller, Jiyang Yu, Stefano Cairo, Liqin Zhu
    Communications Biology.2023;[Epub]     CrossRef
  • An Efficient 5-Aminolevulinic Acid Photodynamic Therapy Treatment for Human Hepatocellular Carcinoma
    Abhishek Kumar, Florian Pecquenard, Martha Baydoun, Alexandre Quilbé, Olivier Moralès, Bertrand Leroux, Lynda Aoudjehane, Filomena Conti, Emmanuel Boleslawski, Nadira Delhem
    International Journal of Molecular Sciences.2023; 24(13): 10426.     CrossRef
  • Glycidamide and cis-2-butene-1,4-dial (BDA) as potential carcinogens and promoters of liver cancer - An in vitro study
    Sofia Gouveia-Fernandes, Armanda Rodrigues, Carolina Nunes, Catarina Charneira, João Nunes, Jacinta Serpa, Alexandra M.M. Antunes
    Food and Chemical Toxicology.2022; 166: 113251.     CrossRef
  • Alpinumisoflavone Impairs Mitochondrial Respiration via Oxidative Stress and MAPK/PI3K Regulation in Hepatocellular Carcinoma Cells
    Hyewon Jang, Jiyeon Ham, Jisoo Song, Gwonhwa Song, Whasun Lim
    Antioxidants.2022; 11(10): 1929.     CrossRef
  • A meta-learning approach to improving radiation response prediction in cancers
    Yuening Zhang, Li Qiu, Yongyong Ren, Zhiwei Cheng, Leijie Li, Siqiong Yao, Chengdong Zhang, Zhiguo Luo, Hui Lu
    Computers in Biology and Medicine.2022; 150: 106163.     CrossRef
  • In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma
    Fredrik Kullenberg, Oliver Degerstedt, Carlemi Calitz, Nataša Pavlović, David Balgoma, Johan Gråsjö, Erik Sjögren, Mikael Hedeland, Femke Heindryckx, Hans Lennernäs
    Cells.2021; 10(7): 1717.     CrossRef
  • Entrainment of superoxide rhythm by menadione in HCT116 colon cancer cells
    Uma Kizhuveetil, Meghana V. Palukuri, Priyanshu Sharma, Devarajan Karunagaran, Raghunathan Rengaswamy, G. K. Suraishkumar
    Scientific Reports.2019;[Epub]     CrossRef
  • Krüppel‐like factor 2 inhibits hepatocarcinogenesis through negative regulation of the Hedgehog pathway
    JinBo Lin, Huifang Tan, Yingjie Nie, Dongwen Wu, Weiji Zheng, Wensong Lin, Zheng Zhu, Bing Yang, Xiaoliang Chen, Tao Chen
    Cancer Science.2019; 110(4): 1220.     CrossRef
  • CMA down-regulates p53 expression through degradation of HMGB1 protein to inhibit irradiation-triggered apoptosis in hepatocellular carcinoma
    Jing-Hua Wu, Jia-Pei Guo, Jun Shi, Hui Wang, Lei-Lei Li, Bin Guo, Dian-Xing Liu, Qing Cao, Zhi-Yong Yuan
    World Journal of Gastroenterology.2017; 23(13): 2308.     CrossRef
  • 9,320 View
  • 78 Download
  • 13 Web of Science
  • Crossref

Case Report

A case of isolated metastatic hepatocellular carcinoma arising from the pelvic bone
Kyu Sik Jung, Kyeong Hye Park, Young Eun Chon, Sa Ra Lee, Young Nyun Park, Do Yun Lee, Jin Sil Seong, Jun Yong Park
Korean J Hepatol 2012;18(1):89-93.
Published online March 22, 2012
DOI: https://doi.org/10.3350/kjhep.2012.18.1.89

Reports of metastatic hepatocellular carcinoma (HCC) without a primary liver tumor are rare. Here we present a case of isolated HCC that had metastasized to the pelvic bone without a primary focus. A 73-year-old man presented with severe back and right-leg pain. Radiological examinations, including computed tomography (CT) and magnetic resonance imaging (MRI), revealed a huge mass on the pelvic bone (13×10 cm). He underwent an incisional biopsy, and the results of the subsequent histological examination were consistent with metastatic hepatocellular carcinoma. The tumor cells were positive for cytokeratin (AE1/AE3), hepatocyte paraffin 1, and glypican-3, and negative for CD56, chromogranin A, and synaptophysin on immunohistochemical staining. Examination of the liver by CT, MRI, positron-emission tomography scan, and angiography produced no evidence of a primary tumor. Radiotherapy and transarterial chemoembolization were performed on the pelvic bone, followed by systemic chemotherapy. These combination treatments resulted in tumor regression with necrotic changes. However, multiple lung metastases developed 1 year after the treatment, and the patient was treated with additional systemic chemotherapy.

Citations

Citations to this article as recorded by  Crossref logo
  • A case of complete response to radiotherapy combined with durvalumab and tremelimumab in a patient with unknown primary hepatocellular carcinoma arising in the lumbar spine
    Aiko Tanaka, Tomokazu Kawaoka, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Clair Nelson Hayes, Daiki Miki, Masataka Tsuge, Shiro Oka
    Clinical Journal of Gastroenterology.2025; 18(1): 107.     CrossRef
  • Hepatocellular carcinoma presenting as an extrahepatic mass: A case report and review of literature
    Wei Kelly Wu, Krutika Patel, Chandrasekhar Padmanabhan, Kamran Idrees
    World Journal of Gastrointestinal Oncology.2024; 16(5): 2241.     CrossRef
  • Solitary extrahepatic hepatocellular carcinoma in vertebrae without a primary lesion in the liver might originate from bone marrow: a case report and new hypothesis based on a review of the literature and the latest findings
    Yukihiro Shirota, Yoshimichi Ueda, Katsuaki Sato, Yasuhito Takeda, Yuji Hodo, Tokio Wakabayashi
    Clinical Journal of Gastroenterology.2022; 15(6): 1115.     CrossRef
  • Chest Wall Swelling in a Baby Boomer: An Unusual Presentation of Primary Hepatocellular Carcinoma
    Venkata Vinod Kumar Matli, Amina Dhahri, Venkatasai Boda Eswara, Linda D Green
    Cureus.2021;[Epub]     CrossRef
  • Foot and Ankle Hepatocellular Carcinoma Metastasis
    Kalind Parashar, Neeta Pandit-Taskar
    Clinical Nuclear Medicine.2016; 41(1): 69.     CrossRef
  • High dose and compartmental target volume may improve patient outcome after radiotherapy for pelvic bone metastases from hepatocellular carcinoma
    Taehyung Kim, Hye Jung Cha, Jun Won Kim, Jinsil Seong, Ik Jae Lee
    Oncotarget.2016; 7(33): 53921.     CrossRef
  • Hepatocellular Carcinoma with Cervical Spine and Pelvic Bone Metastases Presenting as Unknown Primary Neoplasm
    Seawon Hwang, Jieun Lee, Jung Min Lee, Sook Hee Hong, Myung-Ah Lee, Hoo Geun Chun, Ho Jong Chun, Sung Hak Lee, Eun Sun Jung
    The Korean Journal of Gastroenterology.2015; 66(1): 50.     CrossRef
  • Metastatic hepatocellular carcinoma to the pelvis and vertebrae in a patient with chronic hepatitis ‘C’ with unknown primary
    Syed Hussain Abbas, Muhammad Zia Ul Islam Khan, Muhammad Ijaz, Syed Jawad Akhtar Hussain
    BMJ Case Reports.2015; 2015: bcr2014207249.     CrossRef
  • Using qualitative methods to develop a contextually tailored instrument: Lessons learned
    Haeok Lee, Peter Kiang, Minjin Kim, Semira Semino-Asaro, Mary E Colten, Shirley S Tang, Phala Chea, Sonith Peou, Dorcas C Grigg-Saito
    Asia-Pacific Journal of Oncology Nursing.2015; 2(3): 192.     CrossRef
  • Mediastinal Hepatocellular Carcinoma with Unknown Primary: An Unusual and Rare Presentation
    Peng Soon Koh, Mastura Md Yusof, Boon Koon Yoong, Pathmanathan Rajadurai
    Journal of Gastrointestinal Cancer.2014; 45(S1): 74.     CrossRef
  • 9,778 View
  • 45 Download
  • Crossref

Original Articles

The retrospective cohort study for survival rate in patients with advanced hepatocellular carcinoma receiving radiotherapy or palliative care
Hyuk Soo Eun, Min Jung Kim, Hye Jin Kim, Kwang Hun Ko, Hee Seok Moon, Eaum Seok Lee, Seok Hyun Kim, Heon Young Lee, Byung Seok Lee
Korean J Hepatol 2011;17(3):189-198.
Published online September 30, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.3.189
Background/Aims

This study was conducted to investigate the assessment of treatment efficacy of radiotherapy (RT) and other therapeutic modalities compared with palliative care only for treatment with advanced hepatocellular carcinoma (HCC).

Methods

From 2002 to 2010, based on the case of 47 patients with advanced HCC, we have investigated each patients' Child-Pugh's class, ECOG performance, serum level of alpha fetoprotein and other baseline characteristics that is considered to be predictive variables and values for prognosis of HCC. Out of overall patients, the 29 patients who had received RT were selected for one group and the 18 patients who had received only palliative care were classified for the other. The analysis in survival between the two groups was done to investigate the efficacy of RT.

Results

Under the analysis in survival, the mean survival time of total patients group was revealed between 30.1 months and 45.9 months in RT group, while it was 4.8 months in palliative care group, respectively. In the univariate analysis for overall patients, there were significant factors which affected survival rate like as follows: ECOG performance, Child-Pugh's class, the tumor size, the type of tumor, alpha fetoprotein, transarterial chemoembolization, and RT. The regressive analysis in multivariate Cox for total patients. No treatment under radiotherapy and high level of Child-Pugh's class grade were independent predictors of worse overall survival rate in patients. In contrast, for the subset analysis of the twenty-nine patients treated with radiotherapy, the higher serum level of alpha fetoprotein was an independent predictors of worse overall survival rate in patients.

Conclusions

We found that the survival of patients with advanced HCC was better with radiotherapy than with palliative care. Therefore, radiotherapy could be a good option for in patients with advanced HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Characteristics and survival of advanced untreated hepatocellular carcinoma of non-viral etiology
    Senarath Pathiranage Nimasha Ekanayaka, Nathasha Luke, Suchintha Bandara Thilakarathne, Anuradha Dassanayake, Mahiman Bhaagya Gunetilleke, Madunil A. Niriella, Rohan Chaminda Siriwardana
    Indian Journal of Gastroenterology.2024; 43(6): 1176.     CrossRef
  • Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma
    Kuan-Wei Huang, Yu-Tsung Lai, Guann-Jen Chern, Shao-Feng Huang, Chia-Lung Tsai, Yun-Chieh Sung, Cheng-Chin Chiang, Pi-Bei Hwang, Ting-Lun Ho, Rui-Lin Huang, Ting-Yun Shiue, Yunching Chen, Sheng-Kai Wang
    Biomacromolecules.2018; 19(6): 2330.     CrossRef
  • Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis
    Jeong Il Yu, Hee Chul Park
    World Journal of Gastroenterology.2016; 22(30): 6851.     CrossRef
  • 2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2015; 16(3): 465.     CrossRef
  • Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives
    Jan Erik Slotta
    World Journal of Hepatology.2015; 7(9): 1168.     CrossRef
  • Considerations for Radiation Therapy in Hepatocellular Carcinoma: The Radiation Oncologists' Perspective
    Jeong Il Yu, Hee Chul Park
    Digestive Diseases.2014; 32(6): 755.     CrossRef
  • 9,527 View
  • 73 Download
  • Crossref
Efficacy of Transarterial Chemolipiodolization with or without 3-Dimensional Conformal Radiotherapy for Huge HCC with Portal Tumor Thrombosis
Chan Ran You, M.D., Jeong Won Jang, M.D., Seok Hui Kang, M.D., Si Hyun Bae, M.D., Jong Young Choi, M.D., Seung Kew Yoon, M.D., Ihl Bhong Choi, M.D.1, Dong Hoon Lee, M.D.2, Ho Jong Chun, M.D.2, Byung Gil Choi, M.D.2
Korean J Hepatol 2007;13(3):378-386.
Published online September 20, 2007
DOI: https://doi.org/10.3350/kjhep.2007.13.3.378
Background/Aims
The treatment efficacy for advanced hepatocellular carcinoma is poor. This study examined the efficacy and toxicity of 3-dimensional conformal radiotherapy (3D-CRT) in combination with transarterial chemolipiodolization (TACL) for a huge hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). Methods: From March 2001 to November 2004, 49 patients with advanced HCC with PVTT (size>8 cm, modified UICC stage IVa) were enrolled in this retrospective study. Twenty two patients underwent more than 2 cycles of TACL (adriamycin 50 mg/m2, cisplatin 60 mg/m2, 5-fluorouracil 200 mg/m2 every 4-6 weeks) without 3D-CRT, while 27 patients underwent consecutive TACL with 3D-CRT (40-45 Gy for 4-5 weeks) that was started one week after the 1st TACL. The response was assessed by a computed tomography (CT) and the serum alpha-fetoprotein (AFP) level at 1-2 month intervals. Results: The
objective
response rates in the TACL group and TACL with 3D-CRT group were 18% and 48% at 3 months (P=0.051), and 10.5% and 42% at 6 months (P=0.024) respectively. The median survival time was 13 months and 13.5 months in TACL and TACL with 3D-CRT groups, respectively (P=0.502). The treatment response was better in the TACL with 3D-CRT group but there was no significant difference in survival between the two groups. Most toxicities in the two groups were mild, not exceeding grade 1 according to the WHO criteria. Conclusions: For patients with a huge HCC with PVTT, TACL with 3D-CRT achieved some meaningful clinical benefit. Prospective controlled trials will be needed to confirm the real benefit of TACL combined with 3D-CRT. (Korean J Hepatol 2007;13:378-386)

Citations

Citations to this article as recorded by  Crossref logo
  • Multimodal treatment confers best overall survival results in patients with huge hepatocellular carcinoma: a systematic review and network meta-analysis
    Andrea Chierici, Mohamed El Zibawi, Guido Liddo, Rodolphe Anty, Stefano Granieri, Patrick Chevallier, Antonio Iannelli
    HPB.2024; 26(7): 895.     CrossRef
  • Transcatheter arterial chemoembolisation followed by three-dimensional conformal radiotherapy versus transcatheter arterial chemoembolisation alone for primary hepatocellular carcinoma in adults
    Liming Lu, Jingchun Zeng, Zehuai Wen, Chunzhi Tang, Nenggui Xu
    Cochrane Database of Systematic Reviews.2019;[Epub]     CrossRef
  • Advances in non-surgical management of primary liver cancer
    Xiao Chen
    World Journal of Gastroenterology.2014; 20(44): 16630.     CrossRef
  • Multimodality Treatment Involving Radiotherapy for Advanced Liver-Confined Hepatocellular Carcinoma
    Hong In Yoon, Jinsil Seong
    Oncology.2014; 87(Suppl. 1): 90.     CrossRef
  • Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
    Chihwan Choi, Gi Hong Choi, Tae Hyun Kim, Masatoshi Tanaka, Mao-Bin Meng, Jinsil Seong
    Liver Cancer.2014; 3(3-4): 405.     CrossRef
  • Radiotherapeutic Options for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
    Dong Soo Lee, Jinsil Seong
    Liver Cancer.2014; 3(1): 18.     CrossRef
  • Hepatocellular carcinoma with portal vein tumor thrombosis: Improved treatment outcomes with external beam radiation therapy
    Ji‐Yoon Kim, Su‐Mi Chung, Byung‐Ock Choi, Chul‐Seung Kay
    Hepatology Research.2011; 41(9): 813.     CrossRef
  • Successful Treatment of Stereotactic Body Radiation Therapy Combined with Transarterial Chemolipiodolization for Hepatocellular Carcinoma with Biliary Obstruction
    Chan-Kwon Park, Si-Hyun Bae, Hong-Jun Yang, Ho-Jong Chun, Il-Bong Choi, Jong-Young Choi, Seung-Kew Yoon
    The Korean Journal of Internal Medicine.2011; 26(1): 94.     CrossRef
  • Treatment Algorithm for Intermediate and Advanced Stage Hepatocellular Carcinoma: Korea
    Jong Young Choi
    Oncology.2011; 81(s1): 141.     CrossRef
  • Risk of HBV Reactivation According to Viral Status and Treatment Intensity in Patients with Hepatocellular Carcinoma
    Jeong Won Jang, Jung Hyun Kwon, Chan Ran You, Jin Dong Kim, Hyun Young Woo, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Kyu Won Chung
    Antiviral Therapy.2011; 16(7): 969.     CrossRef
  • Approach to radiation therapy in hepatocellular carcinoma
    Shumei Ma, Benzheng Jiao, Xin Liu, Heqing Yi, Dejuan Kong, Lin Gao, Guangtong Zhao, Yu Yang, Xiaodong Liu
    Cancer Treatment Reviews.2010; 36(2): 157.     CrossRef
  • Practice guidelines for management of hepatocellular carcinoma 2009

    The Korean Journal of Hepatology.2009; 15(3): 391.     CrossRef
  • Challenge and Hope in Radiotherapy of Hepatocellular Carcinoma
    Jinsil Seong
    Yonsei Medical Journal.2009; 50(5): 601.     CrossRef
  • 5,894 View
  • 55 Download
  • Crossref
Radiation Therapy for Bone Metastasis from Hepatocellular Carcinoma
Woong Sub Koom, M.D., Jinsil Seong, M.D., Min Jeong Lee. M.D., Hee Cheul Park, M.D., Kwang Hyub Han, M.D.*, Jae Yoon Chon, M.D.*, Young Myoung Moon, M.D.*, and Chang Ok Suh, M.D.
Korean J Hepatol 2002;8(3):304-311.
Background
/Aim: Recent advances in both diagnosis and treatment have markedly improved the prognosis in patients with hepatocellular carcinoma (HCC). Bone metastasis has become a clinical problem in the treatment of HCC patients. The purpose of this study was to evaluate the palliative effect of radiotherapy for painful bone metastasis from HCC. Methods: From January 1991 to June 2000, 51 patients (77 sites) with painful bone metastasis from HCC were retrospectively analyzed. Ages ranged from 21 to 80 years (median 55 years). The male:female ratio was 7.5:1. Synchronous or metachronous bone metastasis was seen in 20 (39%) and 31 patients (61%), respectively. The most common symptom of bone metastasis was pain (45 patients, 88%). Twenty-one patients (41%) had a solitary bone metastasis while 30 (59%) had multiple ones. The sites of bone metastasis, in order of frequency, were the vertebra (38), rib (20), and pelvis (19). The total radiation dose ranged from 12.5 to 50 Gy (median 30 Gy). The Wisconsin Brief Pain Questionnaire was used to evaluate pain response. Results: The overall 1 and 2 year survival rates from the time of bone metastasis were 15% and 4%, respectively. The median survival time was 5 months. Intrahepatic stage(p=0.014), and metastasis to other organs(p=0.019) were significant prognostic factor for survival by univariate analysis. There was, however, no independent prognostic factor on multivariate analysis. Pain relief after radiotherapy was achieved for 56 sites (73%). Conclusion: The expected life span (median 5 months) in this group of patients suggests a strong necessity for effective treatment for symptomatic palliation. Radiation therapy was effective in pain palliation for bone metastasis from HCC, and this could improve patients` quality of life. (Korean J Hepatol 2002;8:304-311)
  • 3,769 View
  • 19 Download

Review

Recent Developments in Radiotherapy of Hepatocellular Carcinoma
Jin Sil Seong
Korean J Hepatol 2004;10(4):241-247.
With the accumulation of clinical experiences, the efficacy of radiotherapy has been recognized in management scheme for HCC. While hepatologists are beginning to show less reluctance for applying radiotherapy to the treatment of HCC, it is necessary that
  • 3,395 View
  • 23 Download
Original Article
Reappraisal of Risk Factors Predicting Liver Complications from Radiotherapy for Hepatocellular Carcinoma
Ik Jae Lee, M.D., Jinsil Seong, M.D., Su Jung Shim, M.D., Kwang Hyub Han, M.D.1, and Chae Yoon Chon, M.D.1
Korean J Hepatol 2006;12(3):420-428.
Background/Aims
Determination of the optimal radiotherapeutic parameters for radiotherapy of hepatocellular carcinoma (HCC) is still under investigation. The purpose of this study is to identify the risk factors associated with radiation-related morbidity. Methods: We evaluated one hundred fifty-eight patients, who were given radiotherapy for HCC between January 1992 and March 2000. Radiation-induced liver disease (RILD) was defined as the development of nonmalignant ascites without disease progression and an anicteric elevation of the alkaline phosphatase level by at least twofold. Gastrointestinal toxicity was assessed by using the RTOG-EORTC scale. Results: Six patients (3.8%) displayed RILD. In these patients, three patients had not responded to other previous treatments. Two patients with portal vein thrombosis or huge sized mass, above 10 cm, showed liver toxicity and two other patients presented with Child-Pugh class B liver cirrhosis. Eight patients (5%) had gastro-duodenal ulcers. In one of these 8 patients, the left lobe close to the stomach was involved and two patients had been treated for gastro-duodenal ulcer. In two more patients, the radiation field, with using anterior/posterior radiation ports, covered a significant volume of the gastrointestinal tract. One of eight patients had been irradiated with a large fraction size (250 cGy). Conclusions: The efforts should be made to reduce the radiation-related complications for hepatocellular carcinoma by considering the volume and the function of remaining liver, the location of tumor, the tumor size and the severity of liver cirrhosis
  • 3,342 View
  • 18 Download